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ABSTRACT OF DISSERTATION

INSIGHTS INTO HEPATIC ALPHA-FETOPROTEIN GENE REGULATION
DURING LIVER DEVELOPMENT AND DISEASE
The liver is an essential organ for cholesterol homeostasis. If this process
becomes dysregulated, cardiovascular disease (CVD) develops. Zinc-fingers and
homeoboxes 2 (Zhx2) as an important hepatic gene regulator and contributes to
CVD. BALB/cJ mice, with mutant Zhx2 allele, have fewer atherosclerotic
plaques compared to other strains on a high fat diet. In my dissertation, I focused
on the liver phenotype in BALB/cJ mice on a high-fat diet and found increased
liver damage compared to wild-type Zhx2 mice. These data indicates that
reduced Zhx2 in the liver leads to CVD resistance, but increases liver damage.
Therefore, Zhx2 has an important role in lipid metabolism and liver function.
Hepatic alpha-fetoprotein (AFP) is expressed abundantly in the fetal liver
and repressed after birth regulated through three enhancers (E1, E2, and E3). E3
activity is restricted to a single layer of hepatocytes surrounding central veins
(pericentral region) along with glutamine synthetase (GS). In my dissertation, I
explore pericentral gene regulation in the adult liver. A GS enhancer (GSe) also
exhibits pericentral activity which, along with E3, is regulated by the -catenin
signaling pathway. Orphan receptors, Rev-erb, Rev-erb, and ROR, contribute
to E3 activity elucidating a potential mechanism for zonation.
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CHAPTER 1
Introduction
Liver Cell Composition
The liver is the largest internal organ in mammals and it plays a key role in metabolic
homeostasis, biosynthesis and xenobiotic clearance [1]. Gestational events in the fetal
liver are crucial for proper development of all hepatic cell types [2]. In mice, the liver bud
forms from hepatoblasts that migrate from the foregut endoderm and invade the septum
transversum mesenchyme; this process begins at about embryonic day 8.5 (e8.5) and is
essential for generating all cell types in the adult liver [3, 4]. Mesenchymal cells include
progenitors for hepatic stellate cells and hepatic fibroblasts [5]. Signals from these cells,
as well as cardiac myocytes, promote the proliferation of hepatoblasts [6] and induce fetal
expression of hepatic genes, including albumin and alpha-fetoprotein (AFP), through the
activation of transcription factors such as Hepatocyte Nuclear Factor 3 (Foxa) and
CCAAT/enhancer-binding protein (C/EBP) [7]. -catenin is a key signaling molecule
(described below in greater detail) important for cell proliferation and expansion of the
liver bud. Several groups have shown the absence of -catenin early during liver
development is embryonic lethal, demonstrating a critical role for -catenin signaling at
this early stage for the liver and other tissues [8-10]. At roughly e13, bipotential
hepatoblasts begin to differentiate into mature hepatocytes [albumin-positive] or biliary
epithelial cells [cytokeratin-19 (CK19)-positive] which are localized to a region that
surrounds the portal vein [11]. As liver maturation continues, biliary epithelial cells form
tubular ducts that collect bile, which is later transported to the gall bladder [11]. catenin protein levels decrease later in liver development, leading to a reduction in
proliferation and ultimately quiescent mature hepatocytes [8]. Gene expression profiles
differ substantially between the neonatal and adult liver, which is due, in large part, to
different hormonal and nutritional signals [12, 13].
Hepatocytes account for 60-70% of the normal liver parenchyma and are involved
in the majority of liver functions, including synthesis of glutamine, bile acid and amino
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acids, gluconeogenesis, urea production, glycogen storage, and xenobiotic detoxification.
In the adult liver, hepatocytes are generally quiescent although they are capable of
proliferation in response to hepatocyte loss [14]. Hepatic stellate cells, in addition to
providing growth signals during development, become the major sites of vitamin A
storage in adults [15]. In response to persistent damage, due to a number of factors
including viral infection and alcohol toxicity, stellate cells are activated and transform
into collagen-depositing fibroblasts [16]. In this regard, stellate cells are important in
chronic injury that leads to liver fibrosis [17]. While activation of stellate cells leads to
injury, depletion of stellate cells reduces the liver’s ability to regenerate and decreases
survival due to hepatocyte apoptosis [18]. Resident macrophages of the liver, called
Kupffer cells, account for about 50% of the macrophages in adult mammals [19].
Kupffer cells can engulf dietary and bacterial toxins, limiting their presence in the
enterohepatic circulation and reducing inflammation [20]; another critical role of Kuppfer
cells is to phagocytose aged erythrocytes [21]. While there is some debate regarding
stem cells in the liver, it is generally agreed that a small population of cells in the portal
triad region, called oval cells, are bi-potent progenitor cells that can give rise to
hepatocytes and biliary epithelial cells [22, 23]. Liver damage caused either by partial
hepatectomy or treatment with hepatotoxic agents such as carbon tetrachloride or
acetaminophen, elicits a coordinated response by all liver cells to induce proper
regeneration through proliferation of quiescent hepatocytes and oval cells [24, 25]. In
summary, a variety of cells in the mature liver must function in a coordinated manner for
the liver to function properly and respond to stimuli; any imbalance can lead to disease
including fibrosis and cirrhosis.
Liver Architecture and Zonation
Proper liver function requires hepatocytes to carry out a myriad of functions. To
facilitate this, the adult liver has a unique structure of repeating hexagonal units called
lobules (Figure 2A). The middle of each lobule contains a central vein, whereas each of
the six corners consists of the portal triad, containing the hepatic artery, portal vein and
bile ducts [1]. Oxygen-rich blood via the hepatic artery and nutrient-rich blood via the
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portal vein enter the liver and flow along sinusoids towards the central vein, where the
blood exits the liver (Figure 2B). Specialized highly fenestrated endothelial cells filter
nutrients into the space of Disse, which separates the baso-lateral sides of hepatocytes
from the sinusoids [26, 27]. Tight junctions between neighboring hepatocytes create the
bile canaliculi which is necessary for the collection of bile released by the apical side of
hepatocytes. Bile flows towards the intrahepatic bile ducts, opposite of blood flow,
towards the portal triad where they are transported via bile ducts to the gall bladder for
storage before release into the small intestine [28]. Kupffer cells reside primarily in the
sinusoids nearer the portal vein where they can sense and phagocytose bacteria, damaged
red blood cells and macromolecules from the circulation [29]. Vitamin A-storing stellate
cells are anchored on the endothelial sinusoid cells in the space of Disse and are more
abundant in regions surrounding the portal triad (periportal regions) [17].
The liver carries out a number of opposing metabolic functions, many of which
cannot occur simultaneously within the same cell. To overcome this, the liver has
developed heterogeneity of gene expression, a fascinating phenomenon called zonal gene
regulation [30]. Certain genes are expressed in specific regions along the portocentral
axis, with some genes expressed solely in pericentral hepatocytes (those surrounding the
central vein) and others expressed in periportal hepatocytes [31] (Figure 2B). Expression
of some of these genes is highly restricted to a layer of one to two hepatocytes in a
particular zone, whereas others have a more diffuse gradient pattern of zonal expression.
The first gene found to exhibit zonal expression was glutamine synthetase (GS) [32]. GS
is expressed in liver, brain and kidney and drives the production of glutamine through a
reaction between ammonia and glutamate [33]. GS is expressed in all hepatocytes in the
neonatal liver but this expression becomes highly restricted in the adult liver to one to
two layers of hepatocytes surrounding the central vein [34]. This pattern of GS
expression is invariant and not influenced by hormones or nutrients so its pattern does not
alter, although the expression of other zonal genes can change in response to external
stimuli. The bulk of ammonia is converted to urea in periportal hepatocytes by
carbamoyl-phosphate synthetase (CPS1), which exhibits higher expression in periportal
hepatocytes [35]. The absence of periportal ammonia-metabolizing enzymes results in
death due to ammonia toxicity [36] and patients who are deficient in CPS1 develop life
3

threatening hyperammoniemia [37]. Ammonia detoxification forming urea and
glutamine are not the only metabolic pathways that exhibit zonal activity.
Gluconeogenesis, required to generate energy, occurs in periportal hepatocytes where the
rate limiting enzyme of the pathway, phosphoenolpyruvate carboxykinase (PEPCK), is
zonally expressed. PEPCK expression is not static but changes in response to bloodborne nutritional signals [38, 39]. In contrast, Glucose-6-phosphatase is found in
pericentral hepatocytes where it converts glucose to glycogen for storage when energy is
not needed [40, 41]. A variety of Cytochrome P450 (CYP) enzymes are crucial proteins
for xenobiotic metabolism and clearance and many are found at highest levels in the
liver. Most CYP enzymes are zonally expressed, mainly in pericentral hepatocytes, but
this can change during uptake of chemicals, such as ethanol or phenobarbital, that must
be metabolized by a specific CYP [42, 43].
Regulation of liver zonation
Although many enzymes exhibit a zonal pattern of expression, the mechanism of
zonal control is not fully understood. One hypothesis is that blood flow along the
portocentral axis creates a gradient of oxygen and/or nutrients that can lead to differential
gene regulation along this axis [44]. Any mechanism must account for how certain
enzymes, including GS, remain static whereas others are dynamic which is found to be
regulated, to a large extent, at the level of transcription. Early transgenic studies showed
that the 2.5 kb region upstream of the GS gene could confer pericentral regulation to a
linked reporter gene. This region contains an enhancer located 2520 to 2148bp upstream
of the transcription start site; other studies identified another enhancer within the first GS
intron [45]. While no obvious trans-factor binding sequence was identified in the 5’
enhancer, this element, when linked to a heterologous promoter, increased reporter gene
activity in human hepatoma HepG2 cells. PEPCK, the classically studied periportal gene
due to its involvement in energy homeostasis, is regulated by many factors.
Gluccocorticoids stimulate PEPCK expression through cyclic AMP (cAMP) binding [46]
as well as gluccocorticoid receptors binding to response elements in the promoter [38].
PEPCK is also activated by the hormones glucagon and repressed by insulin during
4

starvation and refeeding periods, respectively [47]. However, none of these multiple
factors have been identified as being responsible for zonal regulation of the 1kb PEPCK
promoter region.
Investigation into known hepatic transcription factors yielded some potential
insight regarding mechanisms of zonal regulation. Most of these factors show no change
in zonal expression across the liver lobule. However, HNF4 (hepatocyte nuclear factor
4 ) was expressed mainly in pericentral hepatocytes [48]. HNF4 is an orphan nuclear
receptor that functions during development to promote liver specific gene expression in
hepatoblasts and repress mesenchymal genes [49]. Loss of HNF4 in adult hepatocytes
altered zonal gene expression in the adult liver. In particular, GS and several other
pericentral genes were expressed in non-pericentral hepatocytes when HNF4 was
deleted. Zonality of PEPCK was also disrupted with the loss of HNF4, suggesting a
possible role for this factor in zonal regulation [50]. However, HNF4 regulates many
other genes that are not found to have zonal patterns, indicating that HNF4 is not the
sole factor responsible for this regulation [51, 52].
-catenin
-catenin, the downstream target of the canonical wnt signaling pathway, is
involved in a number of biological processes including the control of target genes [53]
and function of adherens junctions with E-cadherin [54, 55]. In the absence of signaling
cytosolic -catenin is post-translationally modified by an inhibitory complex [56] that
includes adenomatus polyposis coli (APC), axin, casein kinase 1 (CK1) and glycogen
synthase kinase B (GSK3B). This complex binds and phosphorylates -catenin at
specific serine and threonine residues which target it for ubiquitin-mediated proteolysis
[56]. Wnt protein binding to a Frizzled receptor activates the signaling pathway, in which
the protein disheveled inactivates the inhibitory complex, allowing -catenin to become
stable and accumulate in the cytoplasm [57-59]. Through a mechanism that is not fully
understood, the stable -catenin translocates to the nucleus to activate gene expression.
While it does not bind directly to DNA, -catenin associates with T-cell factor/Lymphoid
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enhancer factor (TCF/LEF) transcription factors already bound to sites in target genes
[53, 60]. In the absence of -catenin, TCF/LEF recruits co-repressors, including Groucho,
to target genes to actively repress their expression (reviewed in [61]. Upon entering the
nucleus, -catenin interacts with TCF/LEF, resulting in the dissociation of Groucho and
recruitment of CBP/p300 coactivators to activate target gene transcription [62], including
those involved in cell cycle and cell migration [63, 64].
-catenin activation is important for the development of the liver as well as many
other tissues. Before the foregut invades the septum transversum (STM), a gradient of
wnt activation is needed for the appropriate segmentation of the endoderm. At this stage,
wnt signaling is inhibited by fibroblast growth factor (FGF) signaling from the STM to
promote foregut gene expression [65]. -catenin activity is re-established along with
other signals to promote proliferation and expansion of hepatoblasts in the liver bud [10].
At e14 in mice, -catenin levels begin to decrease, leading to undetectable levels at birth
and causing the hepatocytes to slow their rate of proliferation and begin the maturation
process. -catenin expression is reestablished at postnatal day 10 (P10) in mice and
participates in cell-cell adhesion [66] and maintaining stem cell niches [67, 68]. During
liver damage, -catenin is rapidly activated to assist in hepatocyte proliferation [69].
With partial hepatectomy, a loss of -catenin results in a delayed response of
proliferation [70, 71].
Studies of HCC as well as other cancers has revealed a number of mutations in
the Wnt signaling pathway, including loss-of-function mutations in the inhibitory
complex, mainly in APC, and gain-of-function mutations in -catenin [72, 73]. If catenin is not degraded due to these mutations, it becomes constitutively active and
causes uncontrolled proliferation through activation of cyclin D [74]. Cadoret et al,
investigating -catenin mutations in murine HCC, found a correlation with pericentral
gene overexpression in different tumor and cell lines using subtractive hybridization.
These results were corroborated by injecting mice with an adenovirus containing a
mutant -catenin that remains constitutively active (S37A); this results in increased
expression of the pericentral genes GS, OAT and GLT-1. Correlation between GS
expression and active -catenin was found in ~11% of human HCC samples [75]. This
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study provided the first association between -catenin and zonal regulation. A later study
found that the negative regulator APC had a zonal pattern in adult liver with the highest
APC expression in periportal hepatocytes and a gradual decrease towards the central
vein. -catenin staining was mainly membraneous; however, cytosolic accumulation of
-catenin was observed in pericentral hepatocytes. Conditional deletion of APC increased
-catenin activity and increased expression of GS in non-pericentral hepatocytes along
with a loss in periportal gene expression. In contrast, blocking -catenin through
adenoviral-mediated introduction of the Wnt antagonist, dickkopf-1, had the opposite
effect: a loss of pericentral gene expression and increased expression of periportal genes
in pericentral regions [36]. This elegant study provided strong evidence for the role of catenin in liver zonation.
Alpha-Fetoprotein
Alpha-fetoprotein (AFP) is a 65kDa serum glycoprotein that is produced during
fetal development. AFP is predicted to have a number of functions, including a regulator
of osmolarity and transporter of a variety of molecules [76]. During gestation, AFP is
highly expressed in the yolk sac, fetal liver and to a lesser extent in the intestine [77].
Elevated maternal serum AFP levels, monitored during pregnancy, can indicate fetal
neural tube defects [78] as well as chromosome 21 trisomy [79]. AFP is abundantly
expressed in the fetal liver and repressed to nearly undetectable levels during the first few
weeks after birth [80]. AFP is often found reactivated in cancers [81] and during liver
regeneration from expansion and differentiation of the oval cells [82]. HCC tumors also
express AFP that can be detected in serum and therefore, is used as a diagnostic marker
[83].
AFP belongs to the gene family on mouse chromosome 5 that includes albumin,
vitamin D binding protein and alpha-albumin [84-86] (Figure 3A). The AFP regulatory
elements consists of 250 bp minimal promoter as well as three enhancers located
between albumin and AFP [87] at positions 2.5 (E1), 5.0 (E2) and 6.5 (E3) kb upstream
of the AFP transcription start site [87, 88] (Figure 3B). To understand their contribution
to AFP expression, each AFP enhancer was fused individually to a reporter gene
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containing the human -globin promoter linked to the histocompatability class I gene H-2
Dd (βgl-Dd) and analyzed in transgenic mice. The enhancerless gl-Dd transgene had no
activity in any tissue. In contrast, each enhancer could activate gl-Dd to high levels in
the fetal liver and adult liver. Surprisingly, immunohistochemical analysis with anti-Dd
antibodies revealed distinct patterns of expression in the adult liver. E1- and E2-regulated
transgenes were expressed in all hepatocytes with a gradual decrease in a pericentralperiportal direction. E3 activity became highly restricted in one to two hepatocyte layers
around the central vein, the same pattern of endogenous GS expression [89]. Transgenes
with E2 and E3 together exhibited a highly restricted zonal pattern that was identical to
transgenes with E3 alone, demonstrating an active repression of transgenes in nonpericentral hepatocytes mediated by E3 [90].
Based on these data, I hypothesize that β-catenin signaling controls zonal E3
activity in the adult liver. The first part of my dissertation will explore this model (Figure
4) in which Wnt/-catenin signaling is active in pericentral hepatocytes activating the
pericentral genes including E3-gl-Dd. On the other hand, periportal hepatocytes degrade
any cytosolic -catenin and target genes are actively repressed. In addition, I hypothesize
that TCF4 binding sites in E3 and the GS upstream enhancers are required for the
activation. Since both AFP and -catenin have similar developmental profiles and can be
reactivated in HCC, I also hypothesize that -catenin has a role in AFP regulation during
development.
Zhx2
Although the AFP gene is dramatically repressed after birth, the basis for this
silencing is not fully understood. Clues regarding AFP repression have come from
humans with Hereditary Persistence of AFP (HPAFP) and BALB/cJ mice. Several
human pedigrees have found an association between HPAFP mutations in hepatocyte
nuclear factor 1 (HNF1) binding sites in the AFP promoter [91]. The explanation for
HPAFP in BALB/cJ mice is more complex. In 1979, analysis of serum from numerous
inbred mouse strains found that one strain, BALB/cJ, had significantly elevated serum
AFP levels [92]. The locus controlling this trait was called Alpha-fetoprotein regulator 1
8

(Afr1). Furthermore, the Tilghman lab showed that BALB/cJ adult liver AFP mRNA
levels were 10- to 20-fold higher than adult liver AFP levels in other strains (Figure 5A)
[93]. These and other studies suggested that Afr1 was a negative regulator responsible for
postnatal AFP repression and that Afr1 was mutated in BALB/cJ mice. Afr1-mediated
postnatal repression does not occur through the enhancers [94], but through the 250 bp
AFP promoter [95]. Linkage analysis performed in the Spear lab identified a region on
mouse chromosome 15 associated with high levels of AFP as well as high H19, another
target of Afr1. Examination of this region identified a gene encoding zinc-finger and
homeoboxes 2 (Zhx2), a protein predicted to contain two zinc-fingers and four
homeodomains. Further investigation revealed that the BALB/cJ Zhx2 gene contained a
hypomorphic mutation due to insertion of mouse endogenous retroviral (MERV)
element into the first Zhx2 intron, causing aberrant splicing to the element, although
correct splicing occurs approximately 5% of the time [96, 97]. Northern blots show
absence of Zhx2 elevates H19 mRNA while presence of Zhx2 lowers H19 mRNA to
undetectable levels (Figure 5B). A hepatocyte specific transthyretin (TTR) promotes
Zhx2 transgene on a BALB/cJ background corrected the persistent AFP and H19
phenotype, indicating that Zhx2 is responsible for the Afr1 phenotype and demonstrating
the role of Zhx2 in AFP postnatal repression (Perincheri, Peyton et al. 2008).
Zhx2 was originally identified in yeast 2-hybrid studies to interact with either
transcription factor NF-Y and other closely-related family members Zhx1 and Zhx3 [98,
99]. Despite the prediction that Zhx2 encodes a transcription factor and data indicating
that it controls the AFP promoter, there is no direct evidence that it binds the AFP
promoter (unpublished data Morford L., Peterson, M., Spear B.T.). Nuclear run-on
studies indicate that there is no difference in the transcription of AFP and H19 genes
between BALB/cJ and other mouse strains, despite the differences in steady-state AFP
and H19 mRNA levels (Morford L., Peterson, M., Spear, B.T.). This suggests that Zhx2
might function at the posttranscriptional level. Interestingly, cytoplasmic accumulation of
unspliced AFP mRNA is found in wild-type mice, suggesting that Zhx2 might be
involved in pre-mRNA splicing and/or export (Turcios and Peterson, unpublished).
BALB/cJ mice, on the other hand, maintain correct splicing of AFP which could account
for higher AFP mRNA levels in these mice. Since AFP is also frequently reactivated in
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HCC, there is interest in whether Zhx2 is also disregulated in liver cancer. To date, the
data are not clear. One study suggested that Zhx2 was repressed in liver cancer, whereas
another study saw increased Zhx2 in HCC. [100, 101]. Studies from our collaborator in
China, Chunhong Ma (Shandong University), suggested that nuclear localization of Zhx2
might be reduced in HCC. It should also be noted that Zhx2 is not a liver-specific factor
but is ubiquitously expressed [96]. An increasing number of studies have implicated
Zhx2 in erythrocyte development [102], kidney disease [103, 104], B-cell development
[105] and multiple myeloma progression [106].
Liver cholesterol homeostatsis
Cholesterol, a hydrophobic molecule, is required for membrane stability,
establishing membrane microdomains for signaling [107] and is a substrate for producing
steroid hormones and bile acids [108, 109]. Cholesterol can be ingested or can be
synthesized de novo. Complex regulatory mechanisms have evolved to maintain
appropriate physiological cholesterol levels. While all cells are capable of synthesizing
cholesterol, the liver is the main site for cholesterol homeostasis by balancing
biosynthesis, export, uptake and catabolism of cholesterol. Once ingested, cholesterol is
packaged in chylomicrons and transported to the liver via the lymphatic system [110].
Cholesterol is then either metabolized or incorporated into low density lipoproteins
(LDL), which also contain triglycerides and transport cholesterol to peripheral sites.
Reverse cholesterol transport occurs through efflux using ATP-binding cassette
transporter A1 (ABCA1); high density lipoproteins (HDL) transport excess cholesterol
from the periphery back to the liver [111]. Balanced levels of cholesterol need to be
maintained; an excess of LDL in the circulation can lead to atherosclerosis and arterial
cholesterol plaque buildup. This results in cardiovascular disease (CVD), one of the
leading causes of morbidity and mortality in developed countries.
Atherosclerosis is a complex disease with genetic and environmental
contributions. Based on its clinical significance, there is considerable interest in
understanding the biochemical basis for elevated cholesterol and developing improved
strategies to reduce serum cholesterol. Sterol regulatory element binding-proteins
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(SREBP) are critical regulators of genes that control lipogenesis [112]. Under nonstimulated conditions, SREBP proteins are sequestered in the endoreticulum (ER). Upon
stimulation, Sterol sensing SREBP cleavage protein (SCAP) escorts SREBP to the golgi
where it becomes biologically active through cleavage events [113, 114]. This leads to
SREBP accumulation in the nucleus, where it up-regulates genes required to synthesize
triglycerides and/or cholesterol [115]. Importantly, insulin resistance, which often occurs
in obese patients, can lead to de-repression of the de novo synthesis genes resulting in an
overproduction of cholesterol and triglycerides [116]. In response to excess cholesterol,
the rate-limiting bile acid enzyme Cyp7a1 is up-regulated to synthesize bile acids as is
the LDL receptor to remove cholesterol from circulation [117]. Production of bile acids
using cholesterol as the substrate is seen as the most effective way for the removal of
excess cholesterol and one major target for treatment of high cholesterol. Mouse studies
have identified apolipoprotein E (ApoE) as an important regulator of cholesterol
homeostasis; ApoE knockout mice develop atherosclerosis even when they are fed a
normal non-atherogenic diet [118]. Treatments to treat elevated cholesterol in humans
have been developed based on these studies and include statins, to inhibit de novo
cholesterol synthesis [119], and bile acid sequestrants, to reduce cholesterol recycling
from the intestine and increase bile acid synthesis [120].
Various genetic studies, including Quantitative Trait Locus (QTL) mapping, have
been used to identify genes involved in cholesterol-mediated atherosclerosis. The lab of
Dr. Jake Lusis (UCLA) performed QTL mapping using the mouse strains BALB/cJ,
which is resistant to atherosclerosis, and MRL, which is susceptible to atherosclerosis, to
identify loci that govern this trait. One locus identified from this study, located on
chromosome 15, was called hyperlipidemia 2 (Hyplip2) [121]. Higher resolution
mapping localized Hyplip2 to the same interval that contained Zhx2. In collaboration
with the Lusis lab, we have found that Zhx2 is the gene responsible for the Hyplip2
phenotype [122]. These data indicate that Zhx2 also controls genes involved in
cholesterol and triglyceride homeostasis.
Microarray analysis performed by the Lusis lab identified genes that might be
potential targets of Zhx2 [121]. The second part of my thesis involves diet studies using
the strains BALB/cJ, BALB/c, and BALB/cJ mice containing the hepatocyte specific
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Zhx2 transgene. I hypothesize that Zhx2 regulates cholesterol-homeostasis genes,
identified from the microarray study, such that cholesterol is unable to get processed and
cleared, leading to accumulation in the serum. Unexpectedly, mice lacking wildtype
Zhx2 had an increase in serum alanine aminotransferase (ALT) and liver AFP mRNA
levels suggesting Zhx2 protects the liver from lipid-induced damage. This part of my
dissertation will analyze the liver phenotype in BALB/cJ mice maintained on a high fat
diet.
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Figure 1. Embryonic liver development modified from [123]. Endoderm formation (in
yellow) begins at e7 in the mouse embryo. By e8 the patterning of the endoderm is
determined by the gradient of Wnt signaling. Foregut (fg; in red) ultimately developing
into the liver, expresses wnt antagonists to prevent signaling in these cells. The midgut
(mg) and hindgut (hg) have increasing levels of wnt signaling, the highest found within
the hindgut. By e9 the developing liver bud has invaded the STM and begins to express
hepatocyte marker genes including AFP, Albumin and HNF4α. Between e10 and e15 the
liver bud undergoes massive expansion mediated in part by β-catenin as well as other
growth signals. At e13 the expanded hepatoblasts begin differentiating into hepatocytes
or bile epithelial cells. Prior to birth, β-catenin expression has decreased and the
architecture develops as cells mature. After birth, the postnatal liver (in red) continues
maturing while gradually decreasing AFP expression.
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Figure 2. Liver architecture cartoon used with permission from [2]. Hexaganol in shape,
the liver lobule is the basic unit of the liver. A central vein (CV) lies within the center of
the lobule surrounded by hepatocytes radiating outward to the portal triad. Bile duct, the
portal vein and the hepatic artery makes up the portal triad. Blood enters into the lobule at
the portal triad via the HA rich in oxygen and in nutrients from the portal vein flows
toward the central vein. Bile produced by hepatocytes flows opposite of blood towards
the bile duct for collection. Two main zones exist in the liver; periportal hepatocytes
surround the portal triad, alternatively, pericentral hepatocytes surround the central vein.
One well accepted hypothesis for establishing zonation is that blood flow creates a
gradient of oxygen or hormones and other signaling molecules. This gradient therefore
creates differential signaling in periportal hepatocytes that receive more of the molecule
versus pericentral hepatocytes that receive less.
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A.

B.

Figure 3. Gene family and regulatory elements of AFP. A. Chromosomal representation
modified from [124] shows AFP is linked to a gene family on mouse chromosome 5.
Albumin (ALB), AFP and alpha-albumin (AFM) are in close proximity to each other
while vitamin D binding protein (DBP) lies far upstream separated by three unrelated
genes. Duplication events gave rise to these different genes which is reflected by their
similar gene and protein structures. While they all are expressed in the liver, the timing of
each is slightly different. B. In the 14kb intergenic region between AFP and ALB three
enhancers E1, E2 and E3 are located at -2.5, -5.0 and -6.5kb, respectively. This enhancer
region contributes to early fetal liver expression of AFP and ALB but not expression of
the other family members.
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Figure 4. Model for E3 regulation by wtn/β-catenin used with permission from [125].
Based on previous work showing wnt/β-catenin signaling pathway is involved in
zonation, we have developed a working model for β-catenin regulation of E3 in
pericentral hepatocytes. A. This cartoon figure depicts events in periportal hepatocytes. In
these cells the Frizzled receptor is not active therefore any cytosolic b-catenin is
complexed with Axin, APC, GSK3β and CK1. These proteins phosphorylate β-catenin
which is then targeted for degradation by proteosomes. In the nucleus of periportal
hepatocytes proteins are bound to E3 actively repressing expression of the reporter gene
including TCF4, the traditional β-catenin binding partner. B. Pericentral genes, in the
right cartoon, have activated wnt signaling although, the wnt isoform responsible for this
activation is not known. Activated Frizzled receptor results in Disheveled (DSH)
disassembling β-catenin from the inhibitory complex causing cytosolic accumulation.
Translocation of β-catenin into the nucleus occurs through unknown mechanisms where
it activates target genes by associating with bound TCF4 and recruiting co-activators such
as CBP.
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Figure 5. Regulation of AFP by Zhx2. A. Liver RNA was extracted and analyzed for
AFP expression. This was normalized to total mRNA and values were plotted on a log
scale from [93] with permission. Mouse livers at e18.5 express high levels of AFP which
is repressed gradually after birth (B). In C3H and C57BL/6 mice this repression continues
until it is barely detectable by postnatal day 28 (P28). BALB/cJ mice, in red, reduce AFP
after birth although not completely thereby remaining 10 to 20-fold higher compared to
wild-type strains C3H and C57BL6. B. Zhx2 is responsible for the Afr1 phenotype
identified through linkage map analysis. Adult BALB/cJ livers (first two lanes) have very
low endogenous Zhx2 expression observed through northern blot. This is coordinated
with high expression of H19, another known target of the Afr1.When endogenous Zhx2
is present in the third lane, H19 mRNA levels decrease. Hepatic specific expression of a
Transthyretin (TTR)-Zhx2 transgene on a BALB/cJ background decreases liver H19
expression [96]. AFP mRNA expression exhibits the same patterns of H19 with or
without presence of Zhx2 from an endogenous gene or hepatic transgene (not shown).
This data demonstrates Zhx2 is involved in postnatal repression of AFP and TTR-Zhx2
corrects the Afr1 phenotype. Copyright 2005 National Academy of Sciences, U.S.A.
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CHAPTER 2
Materials and Methods
Mice. All transgenic mice generated by the University of Kentucky Transgenic Facility
were housed in the Division of Laboratory Animal Research (DLAR) facility and kept
according to Institutional Animal Care and Use Committee (IACUC) approved protocol.
All mice had access to food and water and were kept on a 12-12hr light-dark cycle. Mice
containing the E3-βgl-Dd transgene or RORα mutant allele were bred with Bl6/C3H mice
(Jackson Lab). Mice containing TTR-Zhx2-Flag transgene were bred with BALB/cJ mice
(Jackson Lab). Hepatocyte β-catenin knockout transgene positive mice were generated
through crosses between βcatfl/fl, Alb-Cre and either E3-βgl-Dd or RGSe-βgl-Dd mice.
Offspring from intercrosses were monitored for presence of Alb-Cre and βgl-Dd.
Genotyping. At approximately 14-days old each mouse pup was given an ear tag for
numbering and 1mm tail snips were taken. To extract the DNA, the tail pieces were
incubated with a lysis solution (100mM Tris-HCl pH 8.5, 5mM EDTA, 200mM NaCl)
with added 2.5 units proteinase K (Sigma). After overnight incubation in a 52oC
waterbath the remaining material was pelleted through centrifugation at 14,000xg for 12
min. The supernatant containing DNA was decanted into isopropanol to precipitate the
DNA. After another centrifugation for 1 min the DNA was washed with 95% ethanol and
dried for 5 min. Resulting DNA was resuspended in 250 uL water with vortexing. 2.5 uL
of DNA was added to 12.5 uL ThermoStart Master Mix (ThermoScientific), 5 uL water
and 5 uL of primer mix using primers in Table 1. 0.2 mL tubes were placed in the
thermocycler for the indicated number of cycles. All samples underwent the same
protocol: 95oC for 15 min, cycles with 95oC 30 sec, annealing temperature for 30 sec,
72oC for 20 sec and then a final 72oC for 5 min. When complete, 5 uL of 6X loading dye
(Fermentas) was added to each sample and mixed by pipetting. 10 uL of sample was
loaded into the wells of a 1.5% w/v agarose (SeaKem) gel along with a 100 bp ladder
(Fermentas). Electrophoresis separation was done at 140V for 45 min in gel box using 1X
TBE. Bands were visualized with UV light and captured using software.
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Cloning. Megaprimer PCR was used to generate TCF4 mutations in E3. Platinum PCR
Supermix High fidelity (Invitrogen) was added to 1uL of 1:10 diluted E3-pGL3 plasmid
along with 400 uM primer mix of pGL3R and E3TCF4mutF (Table 2). After
amplification in the thermocycler, the whole sample was separated with electrophoresis
in a 1.5% agarose gel. 250 bp amplicon was cut out from the gel using a scalpel, weighed
and gel extracted (Gel extraction kit, Qiagen) according to the manufacturer’s protocol.
10 uL of the eluted megaprimer was added to 1 uL of 1:100 diluted E3-pGL3, 12.5 uL of
ThermoStart Taq and 200 uM of pGL3F primer. PCR was run for 35 cycles with
annealing temperature of 45oC and increasing the times during the PCR reaction to 1 min.
Once complete, the 450 bp amplicon was gel extracted and ligated into pGEMTeasy
(Promega) vector according to the kit protocol. After JM109 transformation and miniprep
plasmid DNA extraction (Qiagen), positive colonies, selected through restriction enzyme
digestion, were sent off for sequencing (ACGT). Correct plasmids and pGL3 promoter
were digested with SacI in 50 uL reaction for two hours in 37oC water bath. Afterwards
the plasmids were precipitated by adding 5uL 5M NaCl and 110uL 100% ethanol.
Pelleted DNA was resuspended in 43 uL water and immediately digested with BglII in
the 37oC waterbath for 2 hours. The 400 bp E3TCF4mut fragment and digested pGL3
promoter vector were gel extracted on a 0.75% agarose gel and processed with the gel
extraction kit. After checking eluted DNA on a 1.5% gel 1uL pGL3 promoter was ligated
to 8uL E3TCF4mut fragment with 10 uL 2X buffer and 1 uL ligase. Positive plasmids in
JM109 were maxi prepped as described below.
RGSe was first cloned into pGL3 promoter. RGSe-βgl-Dd in pUC9 was digested
with BamH1 while pGL3 promoter was digested with BglII. pGL3 after digestion was
incubated with 5 units of Antarctic Phosphatase in the supplied buffer (New England
BioLabs) for 15min at 37oC to remove the phosphate groups and then at 65oC for 10 min
to heat inactivate the enzyme. The 350 bp RGSe fragment and 5 kb pGL3 promoter were
gel extracted as described above from a 0.75% gel with the Qiagen gel extraction kit. The
two purified fragments were ligated with 2X buffer and ligase from the pGEMT Promega
kit. Positive clones in JM109 cells monitored with HindIII for orientation were grown up
in maxi prep as described below. For TCF4 mutation in RGSe two PCR reactions were
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performed using 25 uL ThermoStart Taq, 1 uL 1:10 diluted RGSe-βgl-Dd and a
combination of either pUC9F and RGSTCF4mutR (RGS1) and RGSTCF4mutF and βglR
(RGS2). RGS1 115 bp and RGS2 300 bp fragments were gel purified from a 1.5%
agarose gel. Both fragments were ligated into pGEMTeasy according to the kit protocol.
Once positive clones in JM109 were identified both were grown up for maxi prep and
extracted using the Qiagen Maxi Prep kit according to the manufacturer’s protocol. 5 ug
of RGS2 was digested with XmaI, dephosphorylated as described above and purified on a
1.5% gel. 20 ug of RGS1 was digested with XmaI and the 87 bp fragment was purified
from a 12% acrylamide gel through electroelution as described in Maniatis Molecular
Biology. The DNA was extracted through addition of an equal volume of
Phenol:Chloroform:Isoamyl Alcohol (PCI), was ethanol precipitated and the resulting
pellet resuspended in 20 uL water. 10 uL of RGS1 was ligated into RGS2-pGEMT XmaI
digested vector using 2x buffer and ligase from the pGEMTeasy kit. Minipreps of
transformed JM109 cells were digested with BamH1 to determine correct orientation.
Positive colonies were digested with BamH1 to excise the RGSTCF4mut fragment. After
gel purification RGSTCF4mut was ligated into pGL3 promoter BglII digested and
dephosphorylated as described above. Minipreps of RGSmut-pGL3 were digested with
HindIII to find positive inserts and determine correct orientation. The final positive
plasmid was grown up in maxi prep as described below.
Transformations. Plasmids were transformed into JM109 E coli bacteria by incubating
10uL of plasmid DNA with 100uL JM109 cells on ice for 30 min. Cells were heat
shocked for 45 seconds at 45oC and then incubated on ice for 2 minutes. S.O.C. media
was added and the cells were shaken at 37oC for one hour. Cells were then pelleted in a
one minute centrifugation. S.O.C. was decanted and the cells resuspended in the
remaining liquid. Cells were then plated out on LB plates containing ampicillin (Sigma)
and incubated overnight at 37oC. If plasmid was from a low stock of an already maxi
prepped sample, after shaking, 100 uL of sample was placed on the LB plate without
pelleting the cells.
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Miniprep. Individual plated colonies were picked and placed in 1.5mL of LB plus
ampicillin. Cells grew overnight in a shaker at 37C. Cells were pelleted by one minute
centrifugation and the LB media was aspirated. Cells were resuspended in 100 uL of
Plasmid Prep Solution 1 (50mM sucrose, 25mM Tris pH8, 10mM EDTA) through
vortexing. Fresh 200 uL plasmid prep solution 2 (0.2N NaOH, 1%SDS) was added to the
cell mixture and mixed by inversion. 150 uL of 3M potassium acetate was added to each
sample and mixed by inversion. 150 uL Chloroform:Isoamyl Alcohol at 24:1 was added
to each sample and vigorously mixed. Samples were centrifuged for three minutes at
14,000 x g. Interface precipitated was removed with a toothpick and the upper layer was
removed. 900 uL of 100% Ethanol precipitated the plasmid DNA/RNA which was then
pelleted through centrifugation for 3 min at 14,000 x g. All liquid was aspirated and
pellet was resuspended in 100 uL of water. After vortexing 100uL of 3M Ammonium
Acetate (Sigma) was added and mixed by vortexing. 500 uL of 100% ethanol was mixed
by vortexing and spun for 3 min at 14,000 x g. All liquid was removed and the pellet
washed in 95% ethanol. After drying on the bench for 5 minutes the pellet was
resuspended in 50 uL of water.
Maxi Prep. Transformed cells were grown in 450 mL LB with 450 uL amp. After
overnight growth at 37oC bacteria was pelleted by centrifugation in Jouan for 20 min.
Cells were resuspended first in 10 mL of plasmid prep solution 1 then shaken with 20 mL
of plasmid prep solution 2. 10mL KoAc was added and the precipitate was pelleted by
centrifugation in the Jouan. The supernatant was passed through gauze and precipitated
with addition of isopropanol. Pelleted DNA was resuspended with 3 mL (TE) then
cesium chloride (CsCl) and ethidium bromide. Samples were placed in a centrifuge tube,
sealed and spun overnight in the ultra centrifuge at 55,000 x g. Bands isolated were
transferred to a new centrifuge tube with TE-CsCl. After a 6 hour spin isolated bands had
ethidium bromide extracted using isoamyl alcohol. Samples were then placed in dialysis
tubing and dialyzed overnight with 0.5M EDTA and 1M Tris-EDTA. After 6 hours of a
second round of dialysis DNA was ethanol precipitated. DNA concentrations were
measured in the spectrophotometer and diluted to 1ug/uL.
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Cell Culture. Cryopreserved Hep3B, HepG2 and HEK293 cells were removed from
liquid nitrogen and placed in the appropriate media in T75 Flasks. Hep3B and HEK293
cells grow in Dulbecco’s minimal eagle’s media (DMEM, Cellgro) supplemented with
10% fetal bovine serum (FBS, Cellgro), 1% L-glutamine and 1% Pen-Strep (Gibco).
HepG2 cells are grown in media containing 1:1 mix of DMEM: Ham’s F-12(Gibco)
supplemented with 10% FBS, 1% L-glutamine, 1% penstrep and 0.1% insulin (Gibco).
All cells were cultured in the Napco incubator set at 37C and 5% CO2.
Transient transfections. Hep3B cells were seeded onto 12 well plates. The following
day cells were transfected using the calcium phosphate protocol. 43.5 uL water, 5 uL
calcium chloride (CaCl2) and plasmids: 500 ng of reporter, 1 ug of the expression
plasmid along with 12.5 ng of normalizing vector Renilla were mixed together in a
microfuge tube. While the samples were bubbled with air, 50 uL 2X Hepes-buffered
saline (HBS; 280mM Nacl, 1.5mM Na2HPO4, 50mM Hepes, pH 7.1) was added
dropwise and bubbling continued for 30 sec. After 30 min incubation at room
temperature the mixture was added dropwise into the wells. Each sample was made for
duplicate wells. 6 hours later the media was changed by washing the cells with 1X PBS
and at 48 hours the cells were harvested.
Dual luciferase assay. Cells were harvested 48 hours after transfection by washing with
sterile 1X phosphate buffered saline (PBS) and 10 min incubation with 200 uL Glo Lysis
Buffer. Glo lysis collected samples were pelleted with 30 sec 13,000 x g centrifugation.
25 uL of Hep3B or 20 uL of HepG2 supernatant were placed in duplicate into 96-well
luciferase plates (CoStar). Analysis was performed on luminometer that injected 25 uL of
both dual luciferase substrates (Promega) into the designated wells. Luciferase values
were normalized to renilla values.
Nuclear extractions. HEK293 cells were seeded onto 10 cm plates. The following day
cells were transfected using the calcium phosphate protocol containing 15 ug of TCF4
expression plasmid. Six hours later the media was changed and 48 hours the cells were
scrapped from the plate using 1 mL of PBS. Cells were pelleted for 1 min at 13,000 x g
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and supernatant removed. Cell fractions were collected from the cells using the NE-PER
nuclear and cytoplasmic extraction kit (Thermo-scientific). Protein concentrations from
nuclear fractions were analyzed from each sample in duplicate using the BCA protein
concentration assay kit (Peirce) at 562 nm in the spectrophotometer.
Electromobility shift assay (EMSA). Oligos (IDT) in Table 3 were generated based on
sequences from E3 and RGSe enhancers containing the TCF4 site as well as a consensus
TCF4 which were resuspended to a final stock concentration of 1 ug/uL. Oligos were
annealed using 10 ug of each plus 5M NaCl and water and by heating to 75oC for 3
minutes and cooling to room temperature. The products were checked on a 12%
acrylamide gel using a 29:1 bis:acrylamide mixture. 10 uL of wildtype annealed products
were radiolabeled with 32P using T4 kinase (Lucigen) according to manufacturer’s
protocol. After quenching the reaction with 0.5M EDTA the sample was passed through a
centri-spin20 column (Princeton Separations) to collect only the kinased sample.
Radioactive counts of 1 uL of sample in 2 mL of scintillation fluid (Research Products
Int) was measured in scintillation counter. Labeled probes were diluted with water to
15,000 cpm/uL. 5X Binding buffer, dI:dC, nuclear extract and possible cold double
stranded unlabeled probe were incubated on ice for 10 min before 1 uL of probe was
added and incubated for an additional 30 min at room temperature. Samples were then
loaded on a 5% acrylamide gel using a 75:1 bis:acryl mixture and run at 230V for about
1.5 hours at room temperature. After the gel was dried it was placed onto a phosphorus
screen overnight in a cassette in the dark. Screens were analyzed with Storm 860
phosphoimager (ThermoScientific) with ImageQuant software.
Diet Study. 6 week old BALB/cJ females (Jackson Lab) and age matched BALB/c
female mice (Harlan) along with age matched female Zhx2 transgene positive and
negative mice were placed on either normal low fat chow with 6.8% fat or “western
style” chow (Harlan Teklad) with 15.8% of fat from cocoa butter for eight weeks.
Contents of these diets can be found in Table 3 Mice had access to water at all times
during the study. Every week weight measurements for each mouse were recorded and
every other week the mice were fasted for four hours for serum collection.
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ALT measurement. Every two weeks each mouse was fasted for four hours but still had
access to water. Mice were warmed under a heat lamp for increased blood flow and after
5 minutes restrained in a plastic tube. A #20 scalpel blade was used to make a small
incision near the tip of the tail across a vein. Approximately 200 uL of blood was
collected in a serum separator tube (Becton, Dickson Co.). Centrifugation at 13,000 x g
for 1 min separated the serum from red blood cells. 1 uL of serum and 9 uL 0.9% Saline
were incubated with 1 mL prepared ALT solution from the ALT kit (Pointe Scientific).
Kinetic measurements were taken on the Biomate 3 spectrophotometer (Thermo
Scientific) every minute after incubation at 37oC for a total of 3 readings. Differences in
the absorbance readings were calculated and multiplied by the dilution factor 1768 to
determine concentration (IU/L) of ALT in the serum.
RNA extraction and Real-Time PCR. Approximately 100 mg of liver was placed into 1
mL of Trizol (Invitrogen) in 2063 tube and homogenized at highest speed for 30 sec. All
liquid was transferred to 1.5 mL microfuge tube. 200 uL of chloroform was added to each
sample and vigorously mixed for 15 sec. Samples were spun down in 4oC cold room at
10,000 x g for 15 min. The top clear aqueous layer was carefully removed and placed into
a new tube which was then filled with 500 uL of isopropanol. After incubation at room
temperature for 10 min the samples were spun down for 10 min at 10,000 x g at 4oC.
Liquid was decanted off and the RNA pellet washed with 1 mL 95% ethanol. Samples
were spun again for 5 min and the wash fluid removed. Pellets were dried at the bench for
10 min and resuspended in 100 uL water. Complete resuspension was accomplished by
placing the samples in the 52oC waterbath for 10 min. After another round of Trizol
extraction the RNA was quantified at 260 nm using a Biomate 3 spectrophotometer
(Thermo Scientific) by placing 2 uL of RNA in 500 uL of water. Concentration was
determined by applying the dilution factor to the calculation. 1 ug of RNA was processed
into cDNA using qscript kit (Quanta Biosciences) according to the manufacturer’s
instructions and run in the reverse transcriptase protocol in iCycler (BioRad). Each
sample was then diluted 1:5 with water. Quantitative PCR was carried out using 2.5 uL of
diluted cDNA with 10 uL of Sybr Green (Quanta Biosciences), 5 uL of primer mix and
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2.5uL of water. Samples were placed in duplicate in a 96 well plate and covered with film
and analyzed with Bio-rad iCycler. All CT (MyIQ) levels were normalized in ΔΔCT
method to ribosomal gene L30.
Immunohistochemistry. Livers frozen in OCT (Richard-Allen Scientific) were allowed
to acclimate to -20oC 5 minutes prior to sectioning in the Microm HM505 N cryostat.
Slices at 10 um thickness were placed onto glass slides. For transgene activity, surface
staining analysis, the sections were fixed for 10 min in 100% ethanol. After two 10
minute PBS washes the slides were placed in a humidifier chamber at 4oC. Slides were
incubated overnight with a 1:75 mix of H2-Dd FITC antibody in PBS. Slides were then
washed for 3 min and coverslipped using VECTAshield (Invitrogen). For
intracellular/nuclear analysis slides were fixed in 4% paraformaldehyde plus 0.5%
Triton-X for 10 min then washed twice for 10 minutes in PBS plus 0.5% Triton-X.
Blocking occurred for one hour at room temperature with 10% normal sheep serum or
10% normal goat serum. Primary antibody Rabbit anti-GS (Sigma), were incubated
overnight at 4oC in a 1:75 dilution in PBS plus 0.5% Triton-X. After a 3 minute wash the
slides were incubated with respective secondary antibody at 1:100 dilution in PBS plus
0.5% Triton-X for 1.5 hours at 4oC. Slides were coverslipped using VECTAshield.
Pictures were taken on Zeiss Upright Microscope with AxioVision Software.
Oil Red O. Frozen OCT livers were cryosectioned at 10 um thick and placed on slides.
Sections were first fixed in ice cold formalin (Fisher). Sections were then rinsed in water
and equilibrated in propylene glycol (Sigma). Slides were then placed in 60oC 0.5% oil
red o (Sigma) in propylene glycol for 8 min. Sections were first placed in 85% propylene
glycol for 5 min then rinse. Slides were incubated in haematoxylin for 1 min to
counterstain the nuclei blue. After a 3 min rinse in tap water slides were coverslipped
using VECTAshield. Pictures were captured using Ziess Upright Microscope and
AxioVision software.
Statistical analysis. All values within a group were averaged and plotted as mean +/standard deviation. p-values were calculated between two groups using student’s t-test.
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Diet study groups were analyzed with ANOVA followed by Tukey’s test. To determine
significant interaction between strain and type of diet two-way ANOVA analysis was
performed. A p-value less than 0.05 was considered significant.
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Table 1. List of Plasmids
Plasmid Name

Description

pcDNA 3.1

Empty expression vector

pGL3 promoter

Promega SV40 promoter driving luciferase

pGL3 control

Promega SV40 promoter and enhancer luciferase vector

WT-pGL3

wildtype AFP E3 linked to E2 in pGL3 promoter generated by J. Butler

SS-pGL3

NR mutant E3 linked to E2 in pGL3 promoter generated by J. Butler
Mouse E3 cloned into expanded MCS in pGL3 promoter generated by J.
Butler

mE3-pGL3
e

e

RGS -pGL3

PCR amplicon from RGS -Bgl-Dd in pGL3 promoter

mE3mut-pGL3

E3 megaprimer mutation of TCF4 site in pGl3 promoter

e

e

RGS mut-pGL3

RGS mutation of TCF4 site in pGL3 promoter

TOP-Flash

Tandem TCF4 sites - minimal promoter - luciferase

FOP-Flash

Tandem mutant TCF4 sites - minimal promoter - luciferase

Renilla

βcatS37A

Promega CMV driven luciferase vector
Wild-type β -catenin expression plasmid obtained from C. Mao
University of Kentucky
Constitutively active β -catenin expression plasmid obtained from C.
Mao Univeristy of Kentucky

RORα

RORα expression plasmid obtained from J.L.Danan CNRS

Rev-erbα

Rev-erbα expression plasmid obtained from J.L.Danan CNRS

Rev-erbβ

Rev-erbβ expression plasmid obtained from J.L. Danan CNRS
TCF4 expression plasmid obtained from Chunming Liu University of
Kentucky

β-catenin

TCF4
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Table 2. Oligos
Genotyping
βgl-Dd transgene
Cre recombinase
ROR wildtype allele
ROR mutant allele
TTR-Zhx2 transgene
Real-time
AFP
β-catenin
Rev-erbα
PEPCK
OAT
RhBG
Rnase4
GLUT1
Glutaminase2
Glutamine Synthetase
Glut2
Cyp8B1
Lipoprotein Lipase

F
R
F
R
F
R
F
R
F
R

5' CACTCACCAGCGCGGGTCTGAGTC
5' ACACCCTAGGGTTGGCCAATCTACT
5' ACCTGAAGATGTTCGCGATTATCT
5' ACCGTCAGTACGTGAGATATCTT
5’ TCTCCCTTCTCAGTCCTGACA
5’ TATATTCCACCACACGGCAA
5’ GATTGAAAGCTGACTCGTTCC
5’ CGTTTGGCAAACTCCACC
5’ TGTTCCAGAGTCTATCACCG
5’ CCCATAGATTTCACCTCAACC

F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

5' CCGGAAGCCACCGAGGAGGA
5’ TGGGACAGAGGCCGGAGCAG
5’ CTCTTCAGGACAGAGCCAATG
5’ ATGCTCCATCATAGGGTCCA
5' CAAGGCAACACCAAGAATGTTC
5' TTCCCAGATCTCCTGCACAGT
5’ TGGCTACGTCCCTAAGGAA
5’ GGTCCTCCAGATACTTGTCGA
5’ AGGACACTGCCACCCAAAGA
5’ GACGAGCGAGCTTACATGCA
5’ GTGTGGGCTTTACCTTCCTCG
5’ CGCAGAAGTCAGCGTTGAT
5’ GAACGGCCAGATGAACTGTCA
5’ CTGGTTCTTGCCCTGTATCTA
5’ ATGTCCACGACCATCATTGC
5’ ACCTCGTCGTTCTTCTTCCC
5’ AACCCAGTGGTCTGCGCTAT
5’ ACAATGGCACCAGCATTGAC
5’ TTTATCTTGCATCGGGTGTG
5’ TTGATGTTGGAGGTTTCGTG
5’ GAAGACAAGATCACCGGAACCTTGG
5’ CACACCGACGTCATAGCCGAACTGG
5’ CAGAGAAAGCGCTGGACTTC
5’ GGCCCCAGTAGGGAGTAGAC
5’ TGGCTACACCAAGCTGGTGGGA
5’ GGTGAACGTTGTCTAGGGGGTAGT
Oligos continued on next page
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Elovl3
TNFα
L30
Probes
mE3 TCF4

mE3 TCF4 mut
e

RGS TCF4
e

RGS TCF4 mut
TCF4 consensus
TCF4 consensus mut
Cloning
pGL3

E3 TCF4 mut
e

RGS TCF4 mut

F
R
F
R
F
R

5’ CCTCTGGTCCTTCCTGGCA
5’ CGGCGTCATCCGTGTAGATGGC
5′ CATCTTCTCAAAATTCGAGTGACAA
5′ TGGGAGTAGACAAGGTACAACCC
5’ ATGGTGGCCGCAAAGAAGACGAA
5’ CCTCAAAGCTGGACAGTTGTTGGCA

F
R

5’ AGATAAAATTCCTTTGATGAAGGAAAA
5’ TTTTCCTTCATCAAAGGAATTTTATCT
5’
AGATAAAATTCCCGGGATGAAGGAAAA
5’ TTTTCCTTCATCCCGGGAATTTTATCT
5’ CATGGAAGGATCAAAGCAAGCCTGC
5’ GCAGGCTTGCTTTGATCCTTCCATG
5' CATGGAAGGACCCGGGCAAGCCTGC
5’ GCAGGCTTGCCCGGGTCCTTCCATG
5’ GGTACTGGCCCTTTGATCTTTCTGG
5’ CCAGAAAGATCAAAGGGCCAGTACC
5’ GGTACTGGCCCGGGGATCTTTCTGG
5’ CCAGAAAGATCCCCGGGCCAGTACC

F
R
F
R
F
R
F
R
F
R
F
R
F
R
F
R

5’ CAGTGCAAGTGCAGGTGCCAGAAC
5’ GGGACTATGGTTGCTGACTAATTG
5’
AGATAAAATTCCCGGGATGAAGGAAAA
5’ TTTTCCTTCATCCCGGGAATTTTATCT
5' CATGGAAGGACCCGGGCAAGCCTGC
5’ GCAGGCTTGCCCGGGTCCTTCCATG

Copyright© Erica Leigh Clinkenbeard
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CHAPTER 3
β-catenin Positively Regulates AFP E3 and RGSe Pericentral Activity
Introduction
Zonality of enzyme expression compartmentalizes opposing metabolic pathways
in different regions of the adult liver. As described in Chapter 1, numerous liver
enzymes have been shown to be expressed only in hepatocytes around the central vein
(pericentral) or surrounding the portal triad (periportal). While several hypotheses have
been proposed to explain this special expression, the regulatory mechanism has yet to be
fully elucidated. During gestation, many zonal genes are expressed throughout the fetal
liver [34] since architecture has not yet been fully developed. After birth, nutritional
signals from the diet and energy demands that begin during the perinatal period help to
establish the zonal pattern of gene expression observed in the adult liver. Regardless of
the stimulus, intracellular signaling pathways are required to link extracellular events to
the nucleus to govern zonal gene regulation.
An elegant study by Benhamouche et al [36] demonstrated that -catenin
signaling governs pericentral gene regulation in the adult liver. -catenin is the
downstream activator of the wnt signaling pathway. In the absence of Wnt signaling,
cytosolic -catenin is complexed with adenomatous polyposis coli (APC), axin and the
kinases GSK-3 and CK1. This inhibitory complex phosphorylates -catenin at specific
serine residues that signal it for ubiquitin-mediated proteolysis. In the absence of this
inhibitory complex (i.e., when blocked by wnt signaling via the frizzled receptor), catenin is stabilized and can enter the nucleus and regulate target gene expression [126].
In regards to zonal gene regulation, activated -catenin (through the expression of a nondegradable form of -catenin or loss of APC) is associated with increased expression of
pericentral genes including GS and ornithine aminotransferase (OAT), and decreased
expression of phosphoenolpyruvate carboxykinase (PEPCK) and other periportal
enzymes [36, 75]. In contrast, blocking -catenin signaling results in a loss of pericentral
enzymes and increased expression of periportal enzymes [127, 128].
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-catenin does not bind DNA directly, but instead regulates target genes through
several pathways. In the canonical pathway, -catenin controls target genes via
interactions with T cell factor/lymphoid enhancer factor (TCF/LEF) family of factors
[60]. In the absence of -catenin, TCF/LEF proteins are bound to consensus motifs and
silence target genes by recruitment of co-repressors such as Groucho. Upon entry into
the nucleus, -catenin interacts with TCF/LEF proteins, resulting in the dissociation of
repressors and recruitment of the co-activators CBP/p300, leading to target gene
activation [129]. While -catenin is clearly involved in zonal gene regulation, the cisacting elements and trans-acting factors involved in this control have not been identified.
Alpha-fetoprotein (AFP) is expressed abundantly in the fetal liver and is repressed
after birth. While AFP itself is not considered a zonal gene, there are parallels between
AFP silencing and zonal gene control. Perinatal repression of AFP begins near the portal
triad and continues towards the central vein, with pericental hepatocytes being the last
cells to express AFP until the gene is completely silenced. The AFP gene remains
inactive in the adult liver but can be transiently reactivated during liver regeneration and
is frequently activated in hepatocellular carcinoma (HCC) and other cancers. Previous
transgenic studies have shown that three distinct upstream enhancers, each roughly 300
bp in length, contribute to high AFP activity during fetal development. We showed
previously that AFP enhancer 3 (E3) activity in the adult liver is highly restricted to a
single layer of pericentral hepatocytes whereas enhancers E1 and E2 are active in a
broader pattern across the liver lobule [90]. Immunohistochemical staining shows that
hepatic E3 transgene expression overlaps with endogenous GS (Figure 6) suggesting
similar regulation mechanisms. Regulation through E3 is dominant; when E3 and E2 are
linked together on the same transgene, expression in the adult liver is highly restricted to
pericentral hepatocytes as seen with transgenes regulated by E3 alone [90].
Based on previous studies on -catenin and zonal control, we hypothesized that it
was also a key regulator for AFP E3 and enhancers of other pericentral genes. Our lab
previously analyzed the upstream enhancer from the rat GS gene (RGSe) using the gl-Dd
reporter transgene and found that it is also zonally active similarly to endogenous GS.
We also showed by immunohistochemistry that E3 activity overlaps with
unphosphorylated (nuclear) -catenin around the central vein. Hydrodynamic tail vein
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injections of a constitutively active form of -catenin (catS37A) activated E3 transgenes
in non-pericentral hepatocytes. In addition, conditional deletion of -catenin in the livers
of adult mice containing either E3- or RGSe-regulated transgenes resulted in a loss of
transgene expression, along with endogenous GS (Butler, J., Spear, B.T. unpublished
data). Taken together, these data demonstrate that -catenin is required for E3 and RGSe
activity in pericentral hepatocytes.
The work described in this chapter builds on our current model of zonal gene
regulation by -catenin. As mentioned above, -catenin lacks the ability to bind to DNA
itself. Therefore, I hypothesized that TCF4 binding sites would be present in E3 and
RGSe and are required for -catenin-mediated control. Binding site analysis, sequence
alignment and electromobility shift assays all provide data to support this hypothesis.
Furthermore, binding site mutations and cotransfections in cell culture demonstrate an
inability of -catenin to activate the enhancers. Both -catenin and AFP have a somewhat
similar developmental pattern and are both often found reactivated in liver cancer so I
hypothesize that -catenin activates endogenous AFP early in development through its
control of E3. Immunohistochemistry and RNA analysis of postnatal d1 livers provides
evidence in support of this hypothesis.
Results
TCF4 binding sites identified in E3 and RGSe enhancers show high
conservation. AFP E3 is a 340 bp element found 6.5 kb upstream from the AFP
transcription start site (TSS) and RGSe is a 400 bp element isolated from 2.5 kb upstream
of the rat GS TSS. Both were cloned into the gl-Dd reporter cassette.
Immunohistochemistry, using a fluorescent antibody against the membrane-bound Dd
protein, showed that both E3-gl-Dd and RGSe-gl-Dd transgenes were expressed in the
same pericentral region as active -catenin (Figure 7).
The role of -catenin in zonal gene control raises the possibility that TCF/LEF
factors are also involved in this regulation. In several zonal genes, including GS, TCF
sites have been identified and ChIP analysis has shown binding of TCF4 proteins. TCF4
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is a traditional binding partner for -catenin. Further analysis revealed that the TCF site
in RGSe is highly conserved across many species, providing further evidence of the
importance of this site (Table 3A). My analysis of E3 using the transcription element
software search (TESS, University of Pennsylvania) binding site program predicted a
strong candidate TCF binding site near the 3’ end of E3. While deletion analysis of E3
many years ago suggested a role for the 3’ end of E3 in HepG2 cells, the factor(s) that
bind this region of E3 were not identified [88]. This putative TCF site in E3 is also
highly conserved, further suggesting an important role in E3 activity (Table 3B).
TCF4 proteins bind to putative TCF binding sites in both E3 and RGSe
enhancers. Based on the putative site identification, I investigated whether TCF4 is
capable of binding to these sites using electromobility shift assays (EMSA). Nuclear
extracts were prepared from HEK293 cells transfected with a FLAG-tagged TCF4
expression vector. Oligonucleotides, 23 bp in length, were generated to contain either the
TCF sites from E3 (E3-TCF), RGSe (RGSe-TCF), and a consensus TCF sequence
(TCFc); double-stranded versions of these 23-mers with mutated TCF sites were also
prepared. All wildtype double-stranded products were used as radiolabeled probes or as
cold competitors. These data indicated that all three wild-type TCF sites could bind
TCF4 and were effective as cold competitors at a 100X molar excess. None of the
mutant probes could compete. Further evidence that TCF4 was bound to these sites came
from supershifts using anti-FLAG antibodies (Figure 8A-C). These data provide direct
evidence that TCF4 can bind the predicted TCF sites in E3 and RGSe.
β-catenin activates E3 and RGSe enhancers through the predicted TCF4
sites. To provide further evidence of -catenin regulation of E3 and RGSe through the
predicted TCF sites, wild-type and TCF-mutant versions of these enhancers were linked
to the pGL3 luciferase vector. The TCF mutations were generated by PCR-based
megaprimer mutagenesis to incorporate the same mutations as those used in EMSA as
cold competitors. These mutations converted three T nucleotides, which are essential for
TCF4 binding, to G nucleotides; these changes also create a SmaI restriction site. The
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full-length mutant amplicons were purified, cloned into pGEMT-easy and sequenced
before being subcloned into pGL3.
To determine responsiveness to -catenin, wild-type and mutant enhancer-pGL3
reporter constructs were transiently co-transfected into Hep3B cells with wild-type and
constitutively active -catenin (catS37A) expression vectors. TOP-Flash, which
contains tandem repeats of consensus TCF4 binding sites linked to a minimal promoter
driving a luciferase gene and FOP-Flash, identical to TOP-Flash except the TCF sites are
mutated, were used as positive and negative controls, respectively. Hep3B cells were
used since they contain less endogenous -catenin than do HepG2 cells, which are also
frequently used in our lab for transfections. Forty-eight hours after transfections, cell
lysates were prepared. Luciferase levels from the reporter and renilla were measured
using a dual-luciferase assay. TOP-Flash, E3-pGL3 and RGSe-pGL3 exhibited a dosedependent increase in activity in response to catS37A compared to the empty vector
control. In contrast, FOP-flash and TCF4 mutant constructs, E3(tcf-) -pGL3 and
RGSe(mut-)-pGL3, did not respond to increasing catS37A levels. Similar results were
observed using a wild-type -catenin expression construct although these results were not
as dramatic (data not shown). Hep3B cells harbor intact inhibitory -catenin proteins;
therefore a wildtype -catenin construct can undergo degradation while catS37A
construct does not. These data demonstrate that -catenin activation occurs through
TCF4 at these sites in the enhancers. Interestingly, E3(tcf-)-pGL3 and RGSe(tcf-)-pGL3
had increased activity than their corresponding wild-type constructs in the absence of cotransfected -catenin (Figure 9). This result provides further evidence of -catenin
responsiveness. In the absence of -catenin, TCF4 recruits Groucho-family co-repressors
to their cognate sites. Through the action of other positive-acting factors that bind E3 and
RGSe, these enhancers have greater activity when co-repressors cannot be recruited by
the mutated TCF sites are mutated.
β-catenin influences perinatal E3 activity and AFP expression during the
perinatal period. In contrast to the pericentral expression seen in the adult liver, E3-glDd transgenes are expressed in all hepatocytes in the fetal liver [89]. This loss of E3
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activity in periportal hepatocytes occurs during the first few weeks after birth. This
gradual loss of E3 activity after birth led me to consider whether E3 activity in the
perinatal period, when the enhancer is still active in non-pericentral hepatocytes, is also
dependent on -catenin. To test this, I monitored E3-gl-Dd expression by
immunofluorescence with anti-Dd antibodies at postnatal day 1 (p1) in Catliv mice. I
chose p1 rather than prenatal timepoints since hepatic Alb-Cre expression begins late
during fetal development [130]. Similarly to what was seen in the adult liver, E3-gl-Dd
transgenes were expressed at low levels in p1 Catliv livers compared to Catfl/fl livers
(Figure 10A). Transgenes were still expressed sporadically in hepatocytes throughout the
liver; continued expression is likely due to incomplete Cre-mediated deletion of -catenin
in this small population of cells.
Since endogenous AFP expression in the developing liver requires the AFP
enhancer region, I predicted that B-catenin is important for AFP expression in early liver
development. I analyzed hepatic AFP mRNA levels in expression through real-time PCR
in p1 Catliv and wild-type livers. While the reduction of -catenin and AFP levels
varied between mice, we found a significant reduction in AFP mRNA levels when catenin levels were low (Figure 10B). This data suggests that -catenin contributes to
AFP expression in the developing liver.
Discussion
The compartmentalization of function in the adult liver, resulting from the
expression of certain genes in pericentral or periportal regions, enables this organ to carry
out a variety of different, and in some cases, opposing functions. Previous studies have
shown that the -catenin signaling pathway has an important role in regulating a number
of zonally-regulated genes in the adult liver. However, the mechanism by which catenin regulates target genes in the adult liver is not fully understood. Here, we have
shown that two defined enhancer elements that exhibit pericentral activity in the adult
liver, AFP enhancer E3 and the -2.5 kb rat GS enhancer RGSe, are regulated by catenin. Furthermore, we have identified highly conserved TCF/LEF sites in these
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enhancers that are required for -catenin responsiveness. These studies also indicate that
expression of AFP is reduced in the perinatal liver in the absence of -catenin, indicating
that this pathway may also be involved in developmental AFP regulation. Taken
together, these data support a model in which postnatal AFP repression and zonal
regulation are mechanistically related.
While -catenin can control target genes through several pathways, my data
indicate that the canonical pathway involving interactions between -catenin and
TCF/LEF family of DNA binding proteins contributes to E3 and RGSe enhancer activity
in vivo. The ~350 bp E3 and RGSe enhancers were found to contain a single strong
consensus TCF/LEF site, both of which are highly conserved across numerous mammals.
These sites could bind TCF4 in vitro, and both enhancers were activated by wild-type and
the constitutively active S37A variant of -catenin in transient co-transfections. These
data provide strong evidence that the highly conserved TCF/LEF sites in E3 and RGSe
are important for -catenin-mediated regulation. In the absence of co-transfected catenin, the activities of both E3 and RGSe were increased when their respective
TCF/LEF sites were mutated. Since TFC/LEF factors can bind the Groucho family of
co-repressors in the absence of -catenin, it is not surprising that we saw a de-repression
of enhancer activity when TCF/LEF proteins could no longer bind their cognate sites.
While I did not directly test the role of Groucho-related proteins in repressing E3 or
RGSe, these results do raise the question whether these co-repressors also contribute to
zonal gene regulation in the adult liver. In this regard, it is interesting that
overexpression of the Groucho-related co-repressor Grg3 in the H2.35 liver cell line
reduces endogenous AFP activity (Sekiya and Zaret, Molec. Cell, 28:291-303), and at
least one groucho-related protein, Grg5, is expressed in the adult mouse liver (Miyasaka
et al, Eur. J. Biochem, 216:343; Mallo & Gridley, Mech of Develop, 42:67)
-catenin and AFP are both expressed during liver development and reactivated
in HCC which led us to examine a potential relationship. At postnatal d1, mouse livers
lacking -catenin have greatly reduced E3 activity and a significant decrease in AFP
expression. While this suggested -catenin regulates endogenous AFP, no linkage
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between these two is found in HCC tumor samples. These data suggest that AFP
reactivation in HCC is independent of catenin. It should also be considered that E3 is
one of four AFP regulatory elements that govern AFP expression. Regulation occurring
at the other elements may override -catenin activation at E3. E1 and E2 are robustly
active in adult liver for which the mechanism and trans-acting factors are not known. It is
possible activation through E1, E2 or the AFP promoter are the primary sites for AFP
induction in HCC.
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Figure 6. E3 shows pericentral activity in adult liver correlating with endogenous GS
expression. E3 was cloned from the mouse genome and placed into the reporter gene
construct with human β-globin promoter driving MHC class I Dd gene (E3-βgl-Dd).
When the reporter gene is active the protein is detected on the cell surface membrane
through the use of a fluorescent conjugated anti-Dd antibody. Adult livers from E3-βgl-Dd
mice stained for Dd show activity only in hepatocytes directly surrounding the central
vein (green) which coincides with endogenous pericentral GS staining (red).
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E3-βgl-Dd

Active β‐catenin

Overlay

Figure 7. Active -catenin and E3 overlap in pericentral hepatocytes. Adult livers were
dissected and cryosectioned at 10um thick. Liver sections underwent double staining for
E3, using the anti-Dd antibody conjugated to FITC (green) and unphosphorylated active
-catenin TRITC antibody (red). While there is robust background for -catenin,
cytoplasmic accumulation is only observed in pericentral hepatocytes. Overlay of these
two antibodies produce a yellow color indicative of co-localization demonstrating a
relationship between E3 activity and -catenin signaling.

41

Table 3. TCF4 sites from E3 and RGSe are highly conserved. Binding site analysis with
TESS revealed putative TCF4 sites at the 3’end in both E3 and RGSe. DNA sequence for
A) RGSe and B) E3were assembled from multiple species including Human (hum),
Chimpanzee (Chi), Rhesus monkey (Rhe), Lemur (Lem), Horse (Hor), Dog, Cat, Guinea
pig (Gui), Mouse (Mou) and Rat and aligned. TCF4 binding site centered the alignment
flanked by sequences 5’ and 3’ to the site. Based on this analysis the TCF4 binding site
sequence is highly conserved in E3 and RGSe from mouse to human with single
nucleotide polymorphisms observed in a few species in red. Such a high degree of
conservation suggests an important function.
A. RGSe TCF4 site alignment
TCF4 site
Hum
Chi
Rhe
Lem
Dog
Cat
Gui
Rat
Mous

acatgaatgg
aacatgaatgg
acatgaatgg
acatgaacgg
acatgaatgg
acatgaatgg
acatgaaagg
acatgaaagg
acatgaaagg

atcaaagc
atcaaagc
atcaaagc
atcaaagc
atcaaagc
atcaaagc
atcaaagc
atcaaagc
atcaaagc

aaatccattt
aaatccattt
aaatccattt
gaatctcttt
aaatccattt
aaatccattt
aaatccattt
aagcctgctt
aaatccgctt

a/ta/tcaaag(g)

B. E3 TCF4 site alignment
TCF4 site
Hum
Chi
Rhe
Lem
Dog
Cat
Gui
Rat
Mous

atttcacttc
atttcacttt
gtttcccttt
gttttccttc
tcattccttc
tcattccttt
catttcctca
ttttccctcc
gttttccttc

atcaaagg
atcaaagg
atcaaagg
atcaaagg
atcaaagg
atcaaaga
atcaaaag
atcaaagg
atcaaagg

gatcttctcc
gactccgccc
gatcttgtcc
gattttattt
gattttgcct
gattttgcct
gactttactt
aattttatct
aattttatct

a/ta/tcaaag(g)
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‐
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‐
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Antibody:

Mock TCF4 TCF4 TCF4 TCF4 TCF4 TCF4
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‐

‐
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Mouse AFP E3
– TCF4 site
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Nuclear extract: ‐
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‐
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‐

‐

‐

‐
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‐

‐

TCF4
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‐

‐

‐

‐

Flag

Figure 8. The TCF4 protein binds to putative sites within E3 and RGSe. A) Wild-type E3
(E3Tcf4) probe was incubated with 5ug nuclear extracts from HEK293 cells either mock
transfected or expressing TCF4-flag protein. 100X cold competitors were used to assess
specificity of the shifted band. These include cold E3Tcf4, mutant TCF4 site
(E3Tcf4mut), TCF4c and mutant consensus (TCF4cmut). A supershifted band appears
when incubated with the anti-Flag antibody. B) RGSe (RGSeTcf4) probe was incubated
with 5 ug nuclear extracts from HEK293 cells either mock transfected or expressing
TCF4-flag protein. 100X cold competitors were used to assess specificity of the shifted
band. These include cold RGSeTcf4, mutant TCF4 site (RGSeTcf4mut), TCF4c and
mutant consensus (TCF4cmut). A supershifted band appears when incubated with the
anti-flag antibody. C) A synthetic consensus TCF4 (TCF4c) probe was incubated with 5
ug nuclear extracts from HEK293 cells either mock transfected or expressing TCF4-flag
protein. TCF4c was also incubated with 100X cold self, TCF4cmut, E3Tcf4, E3Tcf4mut,
RGSeTcf4 and RGSeTCF4cmut. A supershifted band appears when incubated with the
anti-Flag antibody. TCF4 has the ability to bind to each probe which can be competed
away with all other wild-type probes and not mutant probes. Binding is specific to TCF4
for a supershifted band appears when using the flag antibody.
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Figure 9. -catenin activates enhancer constructs through TCF4 sites. Hep3B cells were
transfected with 0.5ug luciferase reporter, 1.0ug expression construct and 12.5ng Renilla.
Cells were harvested 48 hours post-transfection using Glo Lysis buffer. Supernatants
were measured for luciferase and normalized to Renilla levels to account for transfection
efficiency (Y-axis). All reporter constructs were co-transfected with an empty vector
pcDNA to determine basal luciferase activity. Positive control TOP-Flash (light blue) as
well as wildtype TCF4 constructs E3-pGL3 (light red) and RGSe-pGL3 (light purple)
increased luciferase activity with constitutively active -catenin (catS37A) compared to
empty vector. When the TCF4 sites were mutated in E3(tcf-)-pGL3 (dark red) and
RGSe(tcf-)-pGL3 (dark purple) basal luciferase activity with pcDNA increases compared
to the respective wild-type enhancer construct. The negative control FOP-Flash (dark
blue), E3(tcf-)-pGL3 and RGSe(tcf-)-pGL3 are not more active with increasing catS37A
demonstrating -catenin activation is abolished with mutation of the TCF4 binding site.
Therefore -catenin activates these enhancers via TCF4. TCF4 binding is also important
for repression in the absence of activated -catenin signaling.
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Figure 10. β-catenin regulates E3 and AFP expression after birth. To determine if βcatenin impacts postnatal developmental expression livers from hepatocyte β-catenin
knockout (Catliv) mice were analyzed. A. Sections from d3 livers from β-catenin
wildtype (βcatfl) or Catliv both containing E3-gl-Dd were cryosectioned and
immunohistochemically stained with anti- Dd. βcatfl livers have robust E3 activity around
the central vein, but in more hepatocytes than adult livers. Catliv d3 livers have very
little E3 activity. Sporadic cells that still express the transgene may not have undergone
the cre-recombinase reaction to remove β-catenin. (Magnification, 20X) B. RNA was
extracted from two d1 litters and analyzed for AFP (left two bars) and β-catenin (right
bars) mRNA from βcatfl (black, n=5) and Catliv (shaded, n=7) livers. Real-time RTPCR Ct values from each primer set were normalized to the ribosomal gene L30. βcatenin (Cat) mRNA levels are significantly decreased in knockout livers compared to
βcatfl livers which correlated with a significant decrease of AFP mRNA. β-catenin
expression is crucial during fetal development and also plays a role in regulating AFP
expression in fetal liver development through E3. * and ** p<0.05

Copyright© Erica Leigh Clinkenbeard
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CHAPTER 4
Orphan nuclear receptors ROR and Rev-erb/ regulate AFP enhancer 3
Introduction
The adult liver has a defined architecture consisting of multiple lobules that is
essential for hepatic function. The lobule is a hexagonal structure with the central vein at
the center and portal triads (each consisting of a hepatic artery, portal vein, bile duct) at
each of the six corners of the hexagon (Figure 2). Blood enters the liver through the
hepatic arteries and portal veins, flows through sinusoids along anistomizing plates of
hepatocytes, and exits through the central veins. The distance between each portal triad
and central vein is roughly 15-20 hepatocytes. An active exchange of compounds occurs
between the basolateral surface of hepatocytes and blood. The apical sides of
hepatocytes contain the bile caniculi; bile salts and other compounds are trafficked from
hepatocytes to the caniculi and flow in a retrograde manner to the bile ducts for transport
to the gall bladder.
In 1983, Gebhardt and colleagues discovered that the Glutamine Synthetase (GS)
gene is expressed in a layer of 1-2 hepatocytes surrounding the central veins[32]. Since
then, numerous other hepatic enzymes have been found to be zonally regulated, with
many genes expressed similarly to GS in pericentral regions and other genes expressed in
the region around the portal triad (periportal region). This phenomenon of zonal gene
regulation enables the liver to carry out specific functions in different populations of
hepatocytes. Elegant studies by Perret and colleagues have shown that -catenin is an
important regulator of zonal gene regulation [36]. However, the molecular basis of zonal
gene regulation is still not fully understood.
Our lab has been studying alpha-fetoprotein (AFP) regulation for many years.
The AFP gene is abundantly expressed in the fetal liver but dramatically repressed after
birth. This postnatal silencing can be reversed; the AFP gene is transiently induced in
regenerating liver and frequently reactivated in liver cancer. AFP expression is
controlled by a promoter region and three upstream enhancers, E1, E2 and E3, located
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2.5, 5.0 and 6.5 kb upstream of AFP exon 1, respectively. Each enhancer is roughly 300
bp in length. In our studies of the AFP enhancers in transgenic mice, we found that all
three enhancers continued to be active in the adult liver. E1 and E2 were active in all
hepatocytes, with a gradual reduction in activity in a pericentral-periportal direction. E3,
however, was active only in a layer of 1-2 hepatoctyes surrounding the central veins in a
pattern that was identical to the GS gene. This was the first example of a defined
regulatory element that exhibited zonal activity [89, 90]. We have continued to
investigate E3 activity as a model of zonal gene regulation. Our studies support a model
in which the absence of E3 activity in non-pericentral hepatocytes is due to active
repression.
Once E3 was found to have pericentral activity, we began to focus on factors that
might regulate this pattern. As described in chapter 3, we have identified a TCF4 site at
the 3’ end of E3. However, most studies have focused on the 5’ end of this enhancer.
Three major binding sites have been identified in this region, including a C\EBP site,
FoxA site and a nuclear receptor (NR) site (Fig 11) [131-133]. Nuclear receptors
comprise a large class of transcription factors involved in regulating growth and
homeostasis [134-136]. Many NRs are ligand-inducible transcription factors. Generally,
the NR response element in target genes is tandem or inverted repeats of AGGTCA
separated by two or three nucleotides. However, slight variations in the sequence allow
for gene-specific actions of these receptors [137, 138]
One class of NRs is the orphan nuclear receptor family, appropriately named
since their activating ligand remains unknown or does not exist. Rev-erb was the first
orphan nuclear receptor identified [139]. Interestingly, while Rev-erb maintains the
domain to bind a ligand and has recently been suggested to bind to heme [140, 141], it
cannot undergo a conformational change upon ligand binding. Therefore, Rev-erb acts
as a constitutive transcriptional repressor [142]. Rev-erb can homodimerize, but it can
also bind as a monomer to a half-site or single repeat of the response element, where it
recruits nuclear receptor corepressor (NcoR) [140, 142] and histone deacetylase 3
(HDAC3) to repress target genes [143, 144]. Rev-erb is expressed in metabolically
active tissues including liver, adipose, where it is involved in adipocyte differentiation
[145], and muscle, where its function remains unknown. Loss of Rev-erb in mice results
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in a mild phenotype, but these mice exhibit a disruption in circadian pattern. Rev-erb
and its closely related family member Rev-erb, both regulate the major circadian rhythm
regulator Bmal1 [146]. Monomeric response element binding is also a feature of orphan
nuclear receptor ROR (retinoic-acid orphan receptor ), which binds to a half-site that
is similar to that of to Rev-erb proceeded by an A/T rich region [147]. Unlike Rev-erb,
ROR was observed to bind to the co-activators glucocorticoid receptor-interacting
protein 1 (GRIP-1) and peroxisome proliferator-activated receptor binding protein (PBP)
[148]. Competition between ROR and Rev-erb to the same DNA element was
observed when both proteins were co-expressed, with both Rev-erbs opposing gene
activation by ROR [149].
Having found that -catenin was important in zonal control of E3 activity, we
wanted to determine whether any of the factor binding sites on the 5’ end of E3
contributed to zonal E3 activity. In particular, we were interested in whether any of these
sites contributed to the repression of E3 activity in non-pericentral hepatocytes. As
mentioned previously, our working model is that the absence of E3 activity in this
population of cells is due to active repression. This was based on the fact that a transgene
with E3 and E2 combined had the same pericentral activity as transgenes with E3 alone,
whereas E2-regulated transgenes were active throughout the liver [90]. We generated a
series of E3-E2 containing transgenes in which the NR, C/EBP and FoxA sites were
individually mutated. Transgenes with the FoxA and C/EBP mutations exhibited the
same pericentral activity as wild-type transgenes. However, the mutation in the NR site
had a dramatic effect, resulting in transgene activity throughout the adult liver similarly
to those transgenes with E2 alone (J. Butler, ELC, BTS, in preparation). This indicated
that the NR site is required for repression of E3 activity, in non-pericentral hepatocytes.
Previous EMSA studies from our lab showed that ROR, Rev-erb and Rev-erb were
able to bind to this NR site [133]. Transient transfections also showed that ROR
enhanced E3 activity while both Rev-erb and Rev-erb repressed E3 activity (Figure
12). My work in this chapter continues from these observations. Since there is strong
evidence that ROR is the activator, I predicted E3 activity would be lost in mice lacking
ROR. ROR and the Rev-erb proteins are both involved in circadian rhythm regulation
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and in fact have a circadian pattern themselves. Therefore, I also performed a study to
test if E3 activity has a circadian pattern.
Results
RORα is an important positive regulator of E3 activity. Studies have shown
that the orphan nuclear receptor ROR is normally a positive transcription factor of its
target genes. Transfections and EMSAs performed by a previous graduate student in the
lab, James Butler, indicated that the E3 NR site is regulated by ROR. This result led me
to consider whether ROR controls E3 activity in the adult liver. Unlike other orphan
receptors, such as HNF4, ROR has not been shown to have any zonal pattern of
expression in the adult liver. The Staggerer mutant mouse contains a natural mutation in
the ROR gene, a 6.8kb deletion that results in a complete null allele that cannot express
any of the four ROR isoforms. These mice have altered cerebellular development
resulting in an impaired gait, hence, the name [150]. Staggerer mice are viable for only
3-4 weeks after birth. Heterozygous female mice (RORawt/-) purchased from the Jackson
laboratory were crossed with E3-gl-Dd mice. Transgene positive RORwt/- mice were
then intercrossed to generate E3-positive mice that were RORwt/wt or ROR-/-. Livers
were removed as close to four weeks of age as health of the animal would allow.
Immunohistochemistry of frozen liver sections with anti-Dd antibody showed a dramatic
reduction in E3 activity in the ROR null mice. Even though there is not a complete loss
of E3 activity, it is still only found in hepatocytes directly adjacent to the central vein
(Figure 13).
RORα regulates other pericentral enzymes. Since E3 and GS are similarly
regulated by -catenin (chapter 3) we hypothesized that ROR may also regulate other
pericentral genes. RNA isolated from ROR-/- and littermate RORwt/wt livers were analyzed
by real-time RT-PCR for the expression of pericentral genes GS, OAT, and Rhesus
Monkey Glycoprotein B (RhBG) (Figure 14A) as well as periportal genes PEPCK,
Glutaminase2 and GLUT2 (Figure 14B). All pericentral genes examined showed
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reduced expression in ROR-/- mice compared to the wild-type littermates. Periportal gene
expression was not changed regardless of ROR status.
E3-βgl-Dd does not exhibit a circadian rhythm pattern of expression. ROR
and the Rev-erb proteins have opposing effects on E3 activity in cultured cells, and my
data indicates that RORis a positive regulator of E3 in the adult liver. Assessing the
contribution of the Rev-erb proteins became difficult mainly due to the redundancy of the
two proteins and the requirement for double knockout mice that, at this point, do not
exist. Both Rev-erb proteins and ROR are involved in circadian regulation [151] and
exhibit circadian rhythm changes in expression [152]. We hypothesized that the circadian
pattern changes in these orphan receptors might lead to a circadian change in E3 in vivo.
Adult E3 livers, three in each group, were removed at 4 hour intervals during a 24 hour
time period. RNA analysis using reverse transcriptase PCR (RT-PCR) for Rev-erb
showed expression peaks at 4-8 hours after the light cycle begins. However, RT-PCR
shows no change in E3-gl-Dd transgene expression was detected at any of the time
points (Figure 15).
E3 with a mutant NR site is still activated by RORα but not repressed by
Rev-erb proteins in transient transfections. To examine further the role of the NR
proteins in E3 regulation, co-transfections were performed in Hep3B cells using E3/E2regulated pGL3-luciferase reporter plasmids [with E3 wild-type (WT) or a mutant NR
site (SS)] and expression vectors for ROR, Rev-erb, and Rev-erbFigure 16A-B).
Luciferase activity of WT and SS plasmids are very similar when co-transfected with the
empty vector pcDNA 3.1. Addition of ROR increased luciferase levels from both WT
and SS vectors. In contrast, increasing concentrations of Rev-erb proteins (especially
Rev-erb) dramatically decreased luciferase levels from the WT vector (Figure 16A).
However, the highest levels of the Rev-erb proteins did no affect SS luciferase levels
(Figure 16B). These data demonstrate SS is still activated by ROR but the NR mutation
prevents repression by Rev-erb and Rev-erb
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Discussion
Nuclear receptors are gaining attention due to of their global role in gene
regulation that can be tissue-specific and involved in diseases [153, 154]. The structure of
these proteins lends themselves to being good pharmacological targets since complete
activity requires binding a ligand. The orphan nuclear class of receptors are important
gene regulators even though their ligands have not yet been identified. In particular Reverb and ROR are known to regulate circadian rhythm through competitive regulation
of Bmal1 [151]. Both proteins were also recently shown to regulate energy metabolism.
ROR deficient mice develop severe atherosclerosis on a high fat diet [155] and Rev-erb
mice exhibit dislipidemia [156]. One of the main metabolic tissues is the liver, which
compartmentalizes metabolic pathways. This study shows that ROR and Rev-erb and
Rev-erb play a role in this regulation.
E3 offers a model system for studying this mechanism of zonation. Initial binding
site analysis elucidated a nuclear receptor site at the 5’ end of E3. Classification of the
NR binding site found it was a half-site, thereby limiting potential binding proteins to
orphan nuclear receptors. Previous studies by our lab and others show all of these
candidate orphan nuclear receptors ROR and Rev-erb and Rev-erb bind to the E3 NR
site through EMSA analysis [133]. Regulation by these proteins, observed with in vitro
transfections, is consistent with what is observed at other target genes; ROR increases
E3 activity while Rev-erb and Rev-erb repress E3 activity. My studies build upon
these observations to better understand regulation of E3 via these proteins.
Consistent with ROR activating E3 in vitro, ROR-/- liver lost the majority of E3
activity, although it was not completely absent. Nuclear receptors bind very similar sites
and can occasionally be promiscuous in binding. In particular, chicken ovalbumin
upstream promoter-transcription factor (COUP-TFII) is known to bind to ROR response
elements [157]. This is supported by observations from J. Butler in which COUP-TF
proteins bind to the NR site of E3 by EMSA. Surprisingly, -catenin, another potent
activator of E3 discussed previously, does not seem to compensate and activate E3 in
ROR deficient livers. Competition between ROR and Rev-erb proteins is known to
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occur since they bind the same half site in E3 [149, 151]. It is possible that without
ROR present there is no competition, thus Rev-erb or Rev-erb bind and repress E3 in
pericentral hepatocytes. I also found many pericentral genes have reduced expression in
ROR deficient livers compared to wild-type littermates suggesting ROR plays a positive
role in zonation. Many of these same enzymes are also decreased in -catenin knockout
liver suggesting a potential relationship between -catenin and ROR. -catenin has
recently been found to interact with nuclear receptors [158]. Moreover, a direct
interaction between these two proteins was found in colon cancer; however, in this case,
ROR inhibited -catenin activity [159]. I do not believe this occurs in pericentral
hepatocytes since both proteins are required for full E3 activity. Therefore, it is possible
that cooperation occurs in pericentral hepatocytes between ROR and -catenin to
activate pericentral genes as shown in the model (Figure 17).
This coordination may also not be limited to ROR. HNF4, another orphan
nuclear receptor, was found to have a zonal pattern in the adult liver [48]. If HNF is
disrupted, zonal genes GS and PEPCK lose their normal compartmentalization [50].
Studies examining GS found HNF4 binding sites in close proximity to TCF/LEF
binding sites that coordinated to regulate expression of GS [51]. RGSe, the GS enhancer
which recapitulates zonal activity in vivo, was not examined in these studies. While we
have not identified any ROR binding site in RGSe, we have found a putative HNF4
binding site near the 5’ end.
The NR site in E3 is clearly involved in zonal regulation because when it was
mutated (SS), E3 repression is lost and was expressed in all hepatocytes (Butler J,
unpublished data). Using in vitro transient transfections I found that NR mutant E3 (SS)
still responds to the activator but becomes non-responsive to the repressor. The NR
within E3 is considered a half-site; mutation of the NR should abolish site recognition
and binding capability of both Rev-erb proteins and ROR. SS is linked to E2 for added
activity, an enhancer which has not been well characterized. Therefore it is possible E2
may contain a ROR nuclear receptor site. In an attempt to elucidate the role of Rev-erb
proteins, I performed a circadian rhythm study. Rev-erb and Rev-erb peak in
expression in the liver approximately 4-6 hours after the light cycle begins. Alternatively,
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ROR expression peaks a bit sooner around 2-3 hours after beginning of the light cycle
and begins to decrease while Rev-erb proteins peak [160]. However, E3 transgenes
showed no change in expression levels during the 24 hour period. This is consistent with
the fact that expression of pericentral enzymes, for the most part, is static. While ROR
and Rev-erb participate in zonal regulation, other trans-acting factors could potentially
overcome circadian rhythm pattern changes of these proteins.
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Figure 11. Binding sites identified within AFP E3. Early studies with E3 identified three
important binding sites at the 5’ end of the enhancer depicted in this cartoon. These sites
include binding sequences for a nuclear receptor (NR), C\EBP and FoxA. From chapter 3
we also identified a TCF4 binding site at the 3’ end. E3 transgenes mutated at either the
C\EBP or FoxA binding sites did not alter the zonal activity in adult livers. However, the
E3 transgene with a mutated NR site (SS) in the adult liver gained non-pericental activity
demonstrating the importance of the NR site for compartmentalization of E3 activity.
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Figure 12. E3 is activated by ROR and repressed by Rev-erb/ in HepG2 cells. Cells
were transfected with 0.5 ug of reporter and 1.0 ug of an expression vector and 12.5 ng of
Renilla. 48 hours after transfection cells were harvested with Glo Lysis buffer. Luciferase
was measured from the supernatant and normalized to Renilla levels to account for
transfection efficiency (y-axis). pGL3 promoter (cntrl) and pGL3 control (pGL3) are
luciferase constructs were used as negative and positive controls for the assay in the first
two lanes. The next four lanes are co-transfections of the E3-pGL3 luciferase reporter
with expression vectors as labeled. A pcDNA empty vector (EV) assesses basal activity
from E3-pGL3. Addition of ROR to E3 increased luciferase compared to the empty
vector control. Both Rev-erb and Rev-erb reduced luciferase values as compared to the
empty vector control. This demonstrates the ability of these orphan nuclear receptors to
regulate activity of E3. * p<0.00001, + p<0.0005
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Figure 13. E3 activity is regulated by ROR in vivo. E3-gl-Dd transgenic mice were
crossed to ROR-/- mice to assess hepatic E3 regulation. Livers from four week old
RORwt/wt or ROR-/- mice were sectioned and immunohistochemically stained for E3
activity using the anti- Dd antibody. E3 activity in the ROR-/- liver was dramatically
reduced compared to RORwt/wt liver (Magnification, 20X). Sporadic punctate staining was
observed in ROR-/- livers but it was strictly in pericentral hepatocytes. These observations
show ROR is an important positive regulator of E3 in vivo.
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B.

Figure 14. ROR regulates expression of pericentral but not periportal genes. RNA was
isolated from livers that were RORwt (n=1) or ROR-/- (n=6) genotypes. A. RNA was
analyzed by real-time RT-PCR for expression of pericentral genes including glutamine
synthetase (GS), ornithine aminotransferase (OAT) and Rhesus monkey glycoprotein B
(RhBG). Gene expression was normalized to the ribosomal gene L30. For these
pericentral genes, lacking ROR decreases expression. B. RNA was analyzed by realtime RT-PCR for expression of periportal genes including PEPCK, Glutaminase2 and
GLUT2. Expression levels were normalized to L30. No change in periportal expression is
observed in ROR-/- livers compared to wildtype livers. This suggests that ROR plays a
role in regulating zonality in of pericentral gene expression.
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Figure 15. Circadian rhythm of Rev-erb does not affect expression of E3-gl-Dd.
Livers were dissected from eight week old age matched E3-gl-Dd transgenic mice at 4
hour intervals, at the indicated times, over a 24 hour time period. From these, RNA was
analyzed by RT-PCR for gl-Dd (top panel), Rev-erb (middle panel) expression and
L30 (bottom panel) used as a normalizing control. Rev-erb peaks at the 12p and 4p time
points. No reduction in gl-Dd expression is observed at these time points. At 8p the third
animal was a negative transgenic mouse used as a control for genomic contamination.
This suggests that activity of E3 is static in adult pericentral hepatocytes and does not
respond to circadian pattern changes.
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Figure 16. E3 enhancer containing the NR mutation SS is activated by ROR but not
repressed by Rev-erb or Rev-erb. To see if SS is able to respond to the nuclear
receptors, Hep3B cells were transfected using the calcium phosphate method. A. WT
(E3/E2-pGL3) and B. SS (E3NRmut/E2-pGL3) were co-transfected with either an empty
vector (EV) or increasing concentration of the nuclear receptor expression vectors. 48
hours post transfection cells were collected in Glo Lysis buffer. Supernatants were
analyzed for luciferase levels which then normalized to Renilla to account for
transfection efficiency. ROR activates both WT and SS constructs in a dose dependent
manner compared to the empty vector control. Rev-erb and Rev-erb decreases
luciferase levels from the WT construct in a dose dependent manner. Despite the
presence of the repressor at the highest concentration, SS luciferase levels do not
decrease, demonstrating repression through the NR site is lost when mutated.
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Figure 17. Model for zonal E3 regulation by -catenin and nuclear receptors. In the liver
lobule a gradient exists along the porto-centro axis where APC expression is highest in
periportal hepatocytes and gradually decreases towards the pericentral hepatocytes. Low
APC allows for -catenin accumulation and translocation into the nucleus of pericentral
hepatocytes. -catenin binds to target genes through interaction with TCF4 and ROR to
activate, in this case, E3. Alternatively, high APC in periportal hepatocytes degrades any
cytosolic -catenin. Within the nucleus, TCF4, its co-repressors as well as Rev-erb/
bind to the TCF4 site within E3. While ROR is still present in these cells, Rev-erb
proteins out-compete ROR for binding and contribute to E3 repression.
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CHAPTER 5
Zhx2 protects against liver damage during a high fat diet
Introduction
High fat and high cholesterol diets found in developed countries are primarily
responsible for the epidemic rise in obesity rates as well as increased incidence of
atherosclerosis [161, 162]. Cholesterol, an essential biological compound, is used in cell
membranes for stability and signaling [163] and as a precursor for steroid hormones, bile
acids and vitamin D [164-166]. Cholesterol homeostasis is achieved by balancing de
novo synthesis, ingestion, catabolism and excretion through the feces [167]. Imbalance of
cholesterol and other lipids such as triglycerides can cause diseases such as
atherosclerosis, the leading cause of death in the United States [168], and nonalcoholic
fatty liver disease (NAFLD) [169].
Despite the development of various drugs, current treatments for high cholesterol
are not completely effective. This in part is due to the fact that cholesterol-initiated
disease progression is not fully understood. Due to its essential role, all cells have the
ability to synthesize cholesterol de novo. However, dietary cholesterol can be distributed
to peripheral sites through low density lipoprotein (LDL) packaged in the liver [170].
Unfortunately, LDL has the ability to deposit cholesterol on arterial walls, increasing the
likelihood of atherosclerotic plaque formation and giving LDL the reputation of “bad
cholesterol” [171]. In times of cholesterol excess, high density lipoprotein (HDL) can
transport cholesterol back to the liver to either be converted to bile acids or incorporated
in the emulsified material to be excreted in the feces [172]. HDL has the ability to
remove arterial cholesterol and is therefore thought of as “good cholesterol”. Patients
with highly elevated LDL, carrying high levels of cholesterol and triglycerides, and low
HDL, are at high risk of developing atherosclerosis [173]. Drug treatments, including
statins, which inhibit de novo cholesterol synthesis [174, 175], and bile acid sequestrants
[175], which increase fecal excretion and processing of cholesterol into bile acids, are
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effective in lowering cholesterol levels but they are not able to completely prevent
atherosclerosis.
Atherosclerosis is a complex disorder influenced by multiple environmental and
genetics factors. Historically, such complex traits have been more difficult to study than
monogenic traits. However, the advent of genomic methods have provided new
approaches to study the genetic basis of complex traits. One of these strategies is
Quantitative Trait Locus (QTL) mapping, an unbiased method to identify multiple loci
that contribute to a particular phenotype [176], including serum hyperlipidemia and
atherosclerosis. Several years ago, Jake Lusis (UCLA) carried out a QTL study using
BALB/cJ and MRL inbred strains of mice that are resistant and susceptible, respectively,
to diet-induced atherosclerosis. This study identified several QTLs, including one on
chromosome 15 that was associated with hypertriglyceridemia and was called
hyperlipidemia 2 (Hyplip2). The presence of MRL DNA from this region on a BALB/cJ
background (Congenic15 or Con15) increased incidence of atherosclerotic plaques and
hyperlipidemia compared to a BALB/cJ mouse when mice were on a high fat diet [121].
The chromosome 15 interval containing Hyplip2 includes the gene zinc-finger
and homeobox2 (Zhx2). Zhx2 was originally identified in this region by our lab based on
its ability to control hepatic alpha-fetoprotein (AFP) mRNA levels in the adult liver [96].
In BALB/cJ mice, an endogenous mouse retroviral (MERV) element inserted in the first
Zhx2 intron, causing aberrant splicing and dramatically reducing Zhx2 mRNA and
protein levels [97]. Adult liver AFP levels are elevated in BALB/cJ mice, indicating that
Zhx2 is a repressor of AFP expression. Expression of a Zhx2 transgene in the liver of
BALB/cJ mice results in normal AFP repression, confirming a role for Zhx2 in AFP
silencing [96]. Based on the physical linkage of Zhx2 and Hyplip2, we collaborated with
the Lusis lab to determine whether Zhx2 is responsible for the Hyplip2 phenotype.
Expression of the Zhx2 transgene in BALB/cJ mice led to increased serum triglyceride
and cholesterol levels, indicating that Zhx2 is Hyplip2 [122]. This data also indicates that
Zhx2 regulates liver genes involved in lipid homeostasis.
To better understand the role of Zhx2 in hepatic control of lipids, I have analyzed
the expression of genes in the livers of BALB/cJ, BALB/c and BALB/cJ +/- Zhx2
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transgenic mice on a high fat diet. At the beginning of this study, the only known targets
of Zhx2 were AFP, H19 and Glypican3. Using microarray data provided by the Lusis lab
performed between CON15 and BALB/cJ mice, I have used real-time RT-PCR to
confirm additional Zhx2 targets. Interestingly, these studies also identified a Zhx2dependent hepatic phenotype. When placed on a high fat diet, mice without Zhx2
(BALB/cJ) exhibit increased lipid accumulation, AFP mRNA levels and serum ALT
when compared to mice with Zhx2 (BALB/c and BALB/cJ + Zhx2 transgene). These
data indicate that Zhx2 is hepatoprotective in mice on a high fat diet. I examined potential
inflammatory mediators and stress pathways to explore further the basis of liver damage
in the absence of Zhx2.
Results
To investigate the role of Zhx2 in diet-induced changes in liver gene expression, two
comparisons were made. First, studies were performed in BALB/cJ and BALB/c mice.
These two substrains are highly related, having separated roughly 60 years ago.
However, BALB/c mice have the wild-type Zhx2 allele since the MERV element is
found only in the BALB/cJ substrain. I also carried out experiments in BALB/cJ mice
that do or do not contain the TTR-Zhx2 transgene; this construct contains the liverspecific transthyretin promoter/enhancer linked to a full-length Zhx2 cDNA. These mice
will be referred to as BALB/cJ+Zhx2; Zhx2 levels in the livers of these transgenic mice
are similar to wild-type Zhx2 levels (Morford, L., Turcios, L., Peterson, M., unpubl obs)
As mentioned earlier, BALB/cJ+Zhx2 exhibited increased serum triglyceride levels
compared to BALB/cJ mice when placed on a high fat diet. Age matched female mice
from each strain (n=5) were placed on either normal chow (LF, 6.8% fat) or a high fat
(HF) Harlan Teklad chow (15% fat) for eight weeks; previous studies showed that
atherosclerotic plaque formation occurs during this time period. Weekly measurements
indicated weight gain in all cohorts (Figure 18). By week 8, BALB/cJ mice in both
cohorts on the high fat diet weighed significantly more than their counterparts on normal
chow. A significant interaction of strain and diet on weight gain (p=0.046) was observed
in the BALB/cJ and BALB/c cohort. At the end of 8 weeks, all mice were sacrificed and
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the dissected livers were weighed prior to processing. Livers of all mice on the high fat
chow became enlarged and white in color due to lipid accumulation (Figure 19A). Liver
weight normalized to body weight showed that all cohorts on high fat chow had
significantly increased liver: body weight ratios compared to littermates on normal chow.
A significant interaction was found between strain and diet type for both BALB/cJ and
BALB/cJ+Zhx2 (p=0.018) and BALB/cJ and BALB/c (p=0.012) cohorts.
Zhx2 regulates Cyp8B1, Lpl and Elovl3 in the liver. Zhx2 is predicted to
contain two zinc fingers and four homeodomains [99], hallmarks of nucleic acid binding
proteins. While other data suggest that Zhx2 functions as a transcription factor, data from
our lab in collaboration with Dr. Peterson suggest that Zhx2 might also function at the
posttranscriptional level. Until recently, the known targets of Zhx2 regulation were AFP,
H19 and glypican 3 (Gpc3) [177, 178]. Interestingly, all three of these genes are low in
normal adult liver but are frequently reactivated in liver cancer. I have analyzed other
candidate targets of Zhx2 based on microarray data between CON15 and BALB/cJ mice
provided by the Lusis lab.
Sterol 12-hydroxylase (Cyp8B1) was my first gene of interest due to its
important role in the synthesis of bile acids, which requires cholesterol as a precursor.
Cyp8B1 is the key enzyme for cholic acid production, which determines the
hydrophobicity of bile acid salts [179]. RNA extracted from the livers of each mouse
was analyzed for Cyp8B1 using standard RT-PCR. There was no difference observed
between cohorts on the normal chow (Figure 20A-B). BALB/cJ mice maintain slightly
higher levels of Cyp8B1 compared to BALB/c mice on the high fat chow even though
there is a dramatic reduction in levels compared to the mice on the normal chow (Figure
20B). This difference was not observed with BALB/cJ +/- Zhx2, while there is a
reduction in Cyp8B1 in response to the high fat chow there is no strain specific difference
(Figure 20A). Cyp8B1 is mainly produced in hepatocytes. However, based on
immunohistochemical studies, it is also found in cholangiocytes and Kupffer cells [180].
Since the TTR-Zhx2 transgene is expressed only in hepatocytes, the differences in
Cyp8B1 between BALB/c and BALB/cJ+Zhx2 might be due to Zhx2 expression in nonparenchymal liver cells.
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Another gene of interest from the microarray data was Lipoprotein Lipase (Lpl).
Lpl is known to clear triglycerides from the serum [181], and previous Hyplip2 studies
suggested that mice with normal Zhx2 had reduced triglyceride clearance [182]. Lpl also
has a similar developmental profile to AFP in the liver [183], making Lpl a reasonable
target of Zhx2. Real-time RT-PCR analysis of Lpl showed a 2-fold decrease in steadystate mRNA levels in mice containing wild-type Zhx2 on a normal chow diet. Lpl levels
increased in all mice on the high fat chow with only a significant difference observed
between BALB/c and BALB/cJ cohorts (Figure 21) which was also found to have a
significant interaction of strain and diet type (p=0.033).
Another interesting target gene based on the microarray was Elongation of very
long-chain fatty acid-like 3 (Elovl3). However, whereas other targets are high when
Zhx2 is low, Elovl3 appeared to be regulated in an opposite manner in that its levels were
low when Zhx2 was low. Analysis of Elovl3 mRNA levels by real-time RT-PCR
confirmed that mice on normal chow with wild-type Zhx2 (BALB/c and BALB/cJ+Zhx2)
had significantly higher Elovl3 levels compared to BALB/cJ mice. The high fat diet
significantly reduced Elovl3 to similar levels in all cohorts (Figure 22A-B). Both
BALB/cJ and BALB/cJ+Zhx2 as well as BALB/cJ and BALB/c cohorts were found to
have a significant interaction between strain and diet for Elovl3 expression (p=0.0002
and p=0.00035, respectively)
Reduced hepatic Zhx2 results in increased liver damage in mice on a high-fat
diet. Over the past several years, we have begun to appreciate the implication of
hyperlipidemia on liver function. Nonalcoholic fatty liver disease (NAFLD), which
occurs when lipids accumulate in the liver and is frequently found in obese patients, was
originally considered a benign side effect [184]. However, continued fat accumulation
can lead to increasing damage and inflammation and progress to chronic hepatitis and,
ultimately, HCC [185, 186]. To assess liver damage in my diet study, serum was
collected over the 8-week period and analyzed for Alanine Aminotransferase (ALT).
ALT is abundantly produced by the liver; increased serum ALT levels reflect leakage
from damaged hepatocytes [187]. ALT levels were found to be increased in all groups
during this eight week study (Figure 23A-B). As expected, mice on the high fat chow
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showed a greater ALT increase than those on the normal chow. However, BALB/cJ
exhibited the greatest increased ALT on the high fat diet, suggesting that the absence of
Zhx2 led to increased liver damage.
AFP, a known target of Zhx2, is induced during the regeneration period and can
also be used as a marker of liver damage [188]. Real-time RT-PCR analysis of liver AFP
mRNA from mice on normal chow indicated ~10-fold higher AFP mRNA levels in
BALB/cJ mice compared to mice expressing Zhx2, as expected. In addition, BALB/cJ
on the high fat diet showed a dramatic rise in AFP mRNA levels while BALB/c and
BALB/cJ+Zhx2 AFP levels remained the same (Figure 24). A significant interaction
between diet and strain was observed for the BALB/cJ and BALB/cJ+Zhx2 cohort
(p=0.005) The AFP induction in BALB/cJ on high fat chow is consistent with the ALT
data and provides further evidence of increased liver damage in the absence of Zhx2.
Chronic inflammation, under any circumstance, is detrimental to liver function
and can cause cell death and fibrosis from collagen deposition. Inflammation is found in
NAFLD and is often seen as the “second hit” in disease progression [189]. One proinflammatory cytokine known to be increased in NAFLD patients is Tumor Necrosis
Factor  (TNF) [190]. Therefore, TNF mRNA levels were analyzed as a measure of
inflammation between the different groups of mice. In all liver samples from mice on a
normal chow diet, TNF expression was very low (Figure 25). All mice on a high fat
diet showed a significant increase in TNF levels. However, these levels were the same
regardless of Zhx2 levels, suggesting that TNF cannot account for the increased liver
damage found in BALB/cJ mice on the high fat chow.
Lipid accumulation and histological alterations are greater in BALB/cJ mice
than other groups on high fat chow. At the time of tissue removal all groups on the
high fat diet exhibited gross liver phenotypic differences compared to those on normal
chow. To explore further the liver phenotype, formalin-fixed, paraffin-embedded liver
sections were stained with H&E and analyzed in a “blinded” manner by Dr. Eun Lee, the
liver pathologist at UK. Livers from the different groups on the normal chow had no
differences identifiable by the pathologist. All livers from mice on the high fat diet
showed hepatocyte ballooning, hepatic unrest and neutrophil abscesses (Figure 26A-B).
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However, BALB/c mice exhibited less severe changes than the other groups (Figure
26B). BALB/cJ mice on high fat chow was the only group that showed macrovesicular
lipid droplets, but these were low (<1%). Oil Red O staining was performed on frozen
liver sections to evaluate triglycerides and lipid accumulation. As expected, livers from
all groups on a normal chow had very little staining. In contrast, significant Oil Red O
staining was seen throughout the livers of all mice on the high fat diet. BALB/cJ mice
had substantially more staining than BALB/c and BALB/cJ+Zhx2, indicating that
reduced Zhx2 resulted in greater lipid accumulation (Figure 27A-B).
Discussion
High fat diets in developed countries have resulted in an epidemic rise in obesity
rates as well as associated complications including atherosclerosis and NAFLD.
Currently, drug treatments for atherosclerosis target a reduction in cholesterol, but are
ineffective at a complete reversal of the disease. NAFLD remains under investigation
since pathophysiology and clinical manifestations are not completely understood. There
is no known effective drug treatment for NAFLD although changing diet can reverse
some of the histology of the disease in the liver [191]. These metabolic diseases are
complex due to multiple parameters that contribute to disease progression. A better
understanding of the genetic basis of diet-associated cardiac and liver disease will lead to
better treatment strategies. In collaboration with Jake Lusis, our lab previously showed
that Zhx2 can regulate serum lipid levels and atherosclerosis.
My studies described in this chapter have confirmed several hepatic targets of
Zhx2 predicted by microarray analysis, including Cyp8B1, Lpl, and Elovl3. All of these
genes could contribute to the control of serum cholesterol levels. The bile acid synthesis
gene Cyp8B1 is still expressed in BALB/cJ on high fat chow compared to BALB/c.
However, hepatic Zhx2 transgene expression is unable to completely repress Cyp8B1,
suggesting that other liver cells such as Kupffer and cholangiocytes (also known as bile
duct epithelial cells) may contribute to Cy8B1 expression. Another target of Zhx2 is Lpl;
on normal chow, BALB/cJ have higher Lpl mRNA levels compared to BALB/c and
BALB/cJ+Zhx2. However, Lpl mRNA levels were similar in all strains on the high fat
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diet. A study found an upregulation of Lpl in obese patients and suggest a role in hepatic
steatosis [192]. It is possible that the upregulation of Lpl during high fat diet is an attempt
to clear excess serum triglycerides. However, it unfortunately results in hepatic lipid
accumulation to the detriment of the liver. The final target of Zhx2 described here,
Elovl3, is particularly interesting in that it appears to be positively regulated by Zhx2.
Elovl3 is one of seven family members involved elongation of fatty acids up to C24
[193]. Knockout Elovl3 mice were recently found resistant to diet-induced obesity.
Moreover, reduction in Elovl3 decreased hepatic lipid droplets and also reduced VLDLTG levels in mice fed high fat chow [194]. A combination of elevated Lpl and lower
Elovl3 is potentially why BALB/cJ mice have lower serum triglyceride levels compared
to BALB/c mice on normal chow. More detailed analysis of Elovl3 is being carried out
by another graduate student in the lab (Ren, H. unpublished data).
Genetic changes and altered lipid levels are the “first hit” in NAFLD. It is
inflammation and subsequent liver damage that is the “second hit” to progress the disease
[184]. Without intervention, inflammation and fibrosis can lead to cirrhosis and possible
HCC development. Interestingly, this study shows presence of Zhx2 protects from dietinduced liver damage. Mice expressing Zhx2 had lower serum ALT and no AFP
induction when on the high fat chow. Inflammation is one possible mechanism for liver
damage; pro-inflammatory cytokines are elevated in NAFLD patients [195]. Through
monitoring TNFα mRNA in this study, it increased to similar levels amongst all cohorts
on a high fat chow which could be produced by the Kupffer cells. Accumulated lipids
cause inflammation, but can also put stress on cells, ultimately causing death [196].
Histology and Oil Red O show that BALB/c mice with wild-type Zhx2 have less severe
steatosis and decreased lipid accumulation suggesting less lipid related stress. There are
multiple avenues in which excess lipids cause cell death that will be explored in future
studies to determine the mechanism of damage occurring in BALB/cJ mice.
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Figure 18. All cohorts gain body weight on an eight week high fat chow diet study.
Female mice from the strains A. BALB/cJ and BALB/cJ+Zhx2 or B. BALB/cJ and
BALB/c were placed on either normal chow (LF) or a high fat chow (HF) for 8 weeks.
Weekly weight measurements were averaged and are plotted for each cohort as mean +/standard deviation. * p<0.05
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Figure 19. Liver weight increases with high fat chow feeding. At completion of the eight
week diet study the livers were collected. A. These are representative pictures for the
liver phenotype seen in mice of the study. All strains on chow exhibited a normal liver
phenotype while mice on HF chow had enlarged livers with a white color indicative of
lipid accumulation. B. All dissected livers were weighed and normalized to body weight
and calculated as percent. The liver to body weight ratio was averaged for the cohort and
plotted as mean+standard deviation. All cohorts on HF chow significantly increase
liver:body weight ratios compared to LF cohort. BALB/cJ on HF in both panels had
significantly higher ratios as compared to BALB/cJ+Zhx2 (upper panel) and BALB/c
(lower panel). * p<0.05
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Figure 20. CYP8B1 levels decrease in mice on HF chow. RNA was extracted from each
liver and analyzed by RT-PCR for Cyp8B1 expression and L30 as a normalizing gene. A.
BALB/cJ livers were compared to BALB/cJ+Zhx2 livers on chow or HF. No differences
are observed in cohorts on chow. While there is a decrease in expression on HF there is
no obvious difference between these cohorts. B. BALB/cJ livers were compared to
BALB/c livers on normal chow (chow) or high fat chow (HF). No difference is observed
between the cohorts on chow. Cyp8B1 levels decrease on HF; for BALB/c it is
completely shut off, but still remains detectable in BALB/cJ.
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Figure 21. Lpl increases on a high fat chow. A. RNA collected from BALB/cJ or
BALB/cJ+Zhx2 livers on chow (LF) or high fat chow (HF) were analyzed through Realtime RT-PCR for expression of Lipoprotein Lipase (Lpl). Ribosomal gene L30 was used
as a normalizing control for all samples. Average from n=5 for each group was calculated
and plotted as mean+standard deviation. Lpl is significantly higher in BALB/cJ compared
to BALB/cJ+Zhx2 LF. HF significantly induces Lpl expression; no difference is
observed between the two strains. B. RNA collected from BALB/cJ or BALB/c livers on
LF or HF were analyzed similarly for Lpl. BALB/cJ have significantly higher expression
of Lpl compared to LF BALB/c. While a significant induction of Lpl occurs with HF
groups, BALB/cJ HF livers have significantly higher expression. This data demonstrates
Lpl is a target of Zhx2 regulation. * p<0.05
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Figure 22. Hepatic Elovl3 is positively regulated by Zhx2 in mice on normal chow but
decreases with high fat chow. A. RNA collected from BALB/cJ or BALB/cJ+Zhx2 livers
on chow (LF) or high fat chow (HF) were analyzed through Real-time RT-PCR for
expression of elongation of very long chain fatty acids 3 (Elovl3). Ribosomal gene L30
was used as a normalizing control for all samples. Average from n=5 for each group was
calculated and plotted as mean+standard deviation. Presence of Zhx2 in BALB/cJ+Zhx2
LF results in significantly higher Elovl3 expression. While HF chow causes a reduction
in Elovl3 expression in BALB/cJ+Zhx2, the resultant levels are significantly more than
BALB/cJ. No reduction of Elovl3 is observed in BALB/cJ on HF chow. B. RNA
collected from BALB/cJ or BALB/c livers on chow or HF were analyzed similarly for
Elovl3. Again, LF BALB/c mice had significantly higher expression of Elovl3 compared
to BABL/cJ. In BALB/c mice the HF chow dramatically reduced Elovl3 expression
however this was not different from BALB/cJ levels. No reduction in Elovl3 expression
is observed in BALB/cJ on HF chow. * p<0.05
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Figure 23. Serum ALT levels are induced on a high fat diet. Tail vein blood was
collected from the cohorts A. BALB/cJ and BALB/cJ on either chow (LF) or HF chow
and B. BALB/cJ and BALB/c on either chow or HF chow at week 0 and at the end of the
study, week 8. Serum separate from red blood cells was analyzed from each mouse for
ALT which is an indicator of liver damage. Results were averaged from each mouse in
the group (n=5) and graphed as mean+standard deviation. Mice on the diet study all had
ALT increases. BALB/cJ mice on HF had the highest induction by week 8. Although
levels are higher in BALB/cJ HF they did not reach statistical significance over Zhx2
expressing mice (BALB/cJ+Zhx2 and BALB/c) on HF.
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Figure 24. AFP expression is induced in BALB/cJ mice on HF chow. A. RNA collected
from BALB/cJ or BALB/cJ+Zhx2 livers on chow (LF) or high fat chow (HF) were
analyzed through Real-time RT-PCR for expression of alpha-fetoprotein (AFP).
Ribosomal gene L30 was used as a normalizing control for all samples. Average from
n=5 for each group was calculated and plotted as mean+standard deviation. BALB/cJ
have significantly higher AFP levels compared to LF BALB/cJ +Zhx2. AFP is
dramatically induced in BALB/cJ livers on HF which is not observed in BALB/cJ+Zhx2.
B. RNA was analyzed from BALB/cJ and BALB/c on chow or HF chow similarly for
AFP. Again, BALB/cJ have significantly higher AFP mRNA levels compared to LF
BALB/c. AFP is induced in BALB/cJ on HF chow which does not occur in BALB/c.
This suggests damage is occurring in BALB/cJ livers on HF chow for there to be this
AFP induction. Significance levels * p<0.05
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Figure 25. TNF is induced during HF feeding and is not strain specific. A. RNA
collected from BALB/cJ or BALB/cJ+Zhx2 livers on chow (LF) or high fat chow (HF)
and B. BALB/cJ and BALB/c on chow or HF chow were analyzed through real-time RTPCR for expression of Tumor Necrosis Factor alpha (TNF). Ribosomal gene L30 was
used as a normalizing control for all samples. Average from n=5 for each group was
calculated and plotted as mean+standard deviation. In all cohorts on chow TNF levels
are very low and no difference is observed between strains. HF chow induces TNF
expression significantly (p<0.05) however, there again is no strain specific difference
suggesting inflammation may not be the cause for liver damage. [56]
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Figure 26. Liver Histology. Livers from each mouse in the cohorts A. BALB/cJ and
BALB/cJ+Zhx2 on chow and HF chow and B. BALB/cJ and BALB/c on chow and HF
were formalin fixed and paraffin-embedded. Sections from each were stained with H&E
to examine overall histology. All mice on chow are normal as assessed by a blinded
analysis by a pathologist. All mice on the high fat diet exhibit steatosis (white arrow) as
well as hepatocyte ballooning (dashed arrow). Neutrophil abscesses are also present
(black arrow) in the livers suggesting increased inflammation. BALB/cJ mice in
particular were found to have <1% macrovesicular. These parameters in BALB/c mice
were much less severe suggesting Zhx2 protects the liver. Magnification 20X.
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Figure 27. Oil Red O Staining is less severe in mouse livers expressing Zhx2. Frozen
livers from the cohorts A. BALB/cJ and BALB/cJ+Zhx2 on chow or HF and B. BALB/cJ
and BALB/c on chow or HF. Livers were sectioned at 10 um thickness and stained with
Oil Red O in propylene glycol which stains lipids red. Livers were also counterstained
with haematoxylin to stain nuclei blue. Images show that all mice on chow have small
and few lipid droplets. BALB/cJ livers on HF have very dark red and widespread Oil Red
O staining. Livers expressing Zhx2 (BALB/cJ+Zhx2 and BALB/c) have less robust
staining suggesting these livers have less lipid accumulation. (Magnification, 20X)
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Figure 28. Model of Zhx2 and high fat diet-induced liver damage. In mice on a high fat
chow, lipids including fatty acids, cholesterol and triglycerides are transported to the liver
from the intestine. In BALB/c mice with normal Zhx2 levels (left panel) these lipids are
exported out of the liver leading to excess lipids in the serum causing atherosclerotic
plaque formation. In BALB/cJ mice (right panel), reduced Zhx2 levels lead to
disregulation of target genes resulting in reduced clearance of lipids from the liver. While
decreased serum lipid levels reduce atherosclerosis incidence, excess hepatic lipids
damage the liver and elevate AFP expression and serum ALT levels.
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CHAPTER 6
Conclusions and Future Directions
The liver is an essential organ needed for maintenance of metabolic homeostasis
and xenobiotic clearance. Therefore, the liver has become a organ for studying gene
regulation in development and disease. In our case, we focus on the liver-specific gene
AFP to understand developmental gene regulation as well as liver cancer gene expression
changes. Early work with AFP by the Tilghman lab identified three upstream enhancers
as well as a regulator of AFP postnatal repression [87, 197]. All three enhancers are
important for the developmental hepatic expression for both AFP and its family member
Albumin [198]. Characterization of E3 in particular by Peyton and Ramesh found
pericentral activity in adult livers similar to endogenous pericentral zonal genes providing
the first evidence of cis-acting elements governing zonal regulation [89]. Zhx2, the
postnatal repressor of AFP, was identified in linkage mapping and recently implicated in
other diseases including atherosclerosis. While my work has provided further insights
into E3 regulation and atherosclerosis associated Zhx2, future studies will build upon
these observations to better understand these mechanisms of regulation.
E3, RGSe and β-catenin: Liver zonation is poorly understood, however an
accepted mechanism is that extracellular signals are linked to transcriptional regulation.
E3 and RGSe are the first known cis-acting elements that exhibit zonality and therefore
provide a model system for understanding the regulation. AFP is not a zonal gene and
slight differences between E3 and RGSe activity suggest they might not be regulated in
exactly the same manner. However, one major similarity is the regulation by -catenin.
Previous studies showed an association of -catenin activity with overall liver zonal gene
expression [36, 128]. Utilization of hepatocyte specific -catenin knockout (J. Butler,
manuscript in preparation) showed both enhancer transgenes lost all activity in -catenin/-

livers.
My study presented here identified TCF4 sites at the 3’ end in both enhancers

through which -catenin activates the enhancers. The degree of evolutionary
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conservation of this site in both enhancers suggests an important function. This is
especially evident in E3 since the sequence surrounding the TCF4 site immediately loses
the high degree of conservation. Mutating the TCF4 site in the enhancers prevents
increased activity from -catenin; however, basal activities of these mutant enhancers is
higher compared to wildtype enhancer constructs. In the mouse liver I hypothesize
mutating this site in E3 and RGSe will increase their activity into non-pericentral
hepatocytes. Without active Wnt/ -catenin signaling, bound TCF4 acts as a repressor
through recruitment of co-repressors [61]. If TCF4 is unable to bind to its site, the
enhancer should become de-repressed.
One aspect that continues to confound researchers is the mechanism that drives
the formation of zonality in the liver. While the gradient hypothesis is the most popular, it
remains difficult to study. Ultimately, oxygen and nutrient concentrations are highest at
the portal triad and lowest at the central vein creating a gradient of potential signaling
molecules [44]. Unfortunately, the exact molecules that signal intracellularly to alter gene
expression remain unknown. -catenin, while known as a regulator of zonation, has
recently been found to be important in maintaining stem cells in their niches that
generally have low oxygen concentrations. It was found that hypoxia inducible factor 1
alpha (HIF-1) activated -catenin needed for maintenance [67]. I hypothesize that lower
O2 concentrations at the central vein increases -catenin activity in the pericentral
hepatocytes. To test this hypothesis Hep3B cells, with low endogenous -catenin activity,
could be transfected with TOP-Flash and treated with cobalt chloride (CoCl2) to mimic a
hypoxic environment. If hypoxia activates -catenin, I would expect an increase in TOPFlash luciferase levels. I would also expect similar results if wildtype E3- or RGSe-pGL3
plasmids were used as the reporter construct. Mutated TCF4 sites within E3 and RGSe
enhancer constructs would blunt the activation by -catenin activity.
AFP and -catenin have very similar expression profiles throughout
development of the liver [199]. Developing fetal liver express high levels of AFP and catenin until they are repressed around birth. AFP and -catenin are also re-activated
during liver regeneration for appropriate expansion and repopulation of hepatocytes [71].
Mutations in the negative complex or in -catenin causing over-activation are often found
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in cancers [200]. HCC reactivates AFP and a number of HCC samples harbor these
activating -catenin mutations [72]. To date, no association has been found between AFP
and -catenin in HCC [201]. However, in my study, I found that -catenin regulates AFP
during development since knockout -catenin d1 livers have decreased AFP mRNA
levels. During development, AFP is methylated until it is activated in hepatoblasts [202].
No studies have examined epigenetic changes at the AFP locus after birth. I hypothesize
that the AFP gene undergoes epigenetic alterations after birth that contributes to low
expression in adult liver. DNA methylation could be analyzed through bisulfite
sequencing at both endogenous E3 and the promoter at time points in the liver beginning
after birth continuing to adulthood. DNA methylation is typically preceded by other
chromatin changes including nucleosome positioning. This type of regulation occurs very
early in development when the stem cell markers OCT4 and Nanog are silenced. When
the upstream enhancer of OCT4 and proximal Nanog enhancer become occupied with
nucleosomes the element becomes less accessible to activating proteins [203]. ChIP
analysis of histones 3 and 4 (H3 and H4) on the regulatory cis-elements of AFP could be
done pre- and postnatally to determine if nucleosome positioning changes especially at
the endogenous enhancers. It is possible that other pathways during HCC development
activate AFP more robustly at earlier time points compared to -catenin and this
regulation occurs within the other regulatory elements. Ras and myc are oncogenes that
are often activated in HCC [204]. Tumor suppressor p53 is often found repressed either
through mutations or hypermethylation which can also occur in HCC [205]. AFP
upstream region at -3.6kb is found to bind to myc and the AFP promoter has a Foxa/p53
binding site [206, 207]. Both could therefore be potential sites for AFP activation in HCC
independent of -catenin status.
E3, RGSe and nuclear receptors. Both the AFP E3 and RGSe enhancers are
approximately 300-350bp in length which can potentially contain many protein binding
sites. Besides the TCF4 site at the 3’-end, E3 contains three characterized binding sites at
the 5’-end. Only the nuclear receptor site is involved in maintaining pericentral activity of
E3 which binds ROR and Rev-erb proteins [133]. In my study I show ROR is an
important positive regulator of E3 because ROR null mice have dramatically reduced
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E3 transgene activity. There is not a complete loss of E3 activity like in -catenin
knockout livers suggesting that there is possibly another factor that is able to activate the
enhancer but not to the level of ROR. Based on previous data from the lab as well as
studies performed in chapter 4, -catenin and ROR are needed for full activity of E3. catenin has recently been shown to interact with nuclear receptors [158] so it is
conceivable that there may be an interaction between -catenin and ROR occurring in
E3. In EMSA, RORα binds to the E3 NR site probe. Including the active -catenin
antibody resulted in a supershifted band suggesting an interaction between RORα and catenin. These interactions unfortunately were not corroborated utilizing coimmunoprecipitations (Butler, J. unpublished). One interesting observation made by J.
Butler was that ROR has a slight zonal pattern of expression where the highest levels of
proteins, detected by immunofluorescence, are in pericentral hepatocytes. Based on some
recent data there also may be an indirect interaction between ROR and -catenin via
HIF-1. As mentioned above, HIF-1 has been shown to activate -catenin, but it can
also activate ROR[208]. Moreover, ROR is able to activate HIF-1 creating a feedforward mechanism of continuous activation [209]. I hypothesize that ROR is able to
activate HIF-1 which activates -catenin in pericentral hepatocytes. To test this
hypothesis in vitro, Hep3B cells could be co-transfected with RORα expression plasmid
and TOP-Flash control plasmid. If β-catenin is activated luciferase from TOP-flash will
increase. To date no RORα binding site is identified for RGSe so the results should be
similar to TOP-flash. If this is occurring in the mouse liver then immunohistochemistry
for active -catenin in ROR-/- mice should also be reduced.
When Peyton linked E3 to E2 in the reporter transgene the regulation occurring at
E3 was dominant, and again, only active in pericentral hepatocytes [90]. Mutation of the
nuclear receptor in the E3-E2-gl-Dd changed the pattern of activity to that of E2
demonstrating active repression of E3 is occurring in the non-pericentral hepatocytes
[90]. The proteins Rev-erb and Rev-erb are known repressors and can bind to the NR
site along with the activator ROR. My data is consistent with SS transgenics in that the
NR mutation in E3-E2-pGL3 is not responsive to either Rev-erb or Rev-erb but
surprisingly maintains responsiveness to ROR. This could be due to added activity
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provided by E2 which is not as well characterized or studied enhancer. To rule out ROR
binding in E2, binding site analysis with TESS could identify any putative orphan nuclear
receptor sites. If any exist, EMSA can show whether the ROR protein is capable of
binding to any putative sites. Transient transfection with E2 alone in pGL3, if activated
by ROR, would show an increase in acitivity when ROR is co-transfected. I have also
determined a cloning strategy to place SS mutant E3 alone in pGL3. While it may have
low baseline activity, if my hypothesis is correct, activity will increase in presense of
ROR. Our working hypothesis is that in pericentral hepatocytes ROR is bound to the
nuclear receptor site while Rev-erb or Rev-erb is bound in non-pericentral
hepatocytes. To test this hypothesis we are currently generating mice that contain the
MHC Class 1 Ld gene driven by the PEPCK promoter; so transgene expression is only
detected in periportal hepatocytes [210]. Transgene positive mice will then be bred to E3gl-Dd mice to establish mice with reporter genes expressed in periportal (Ld) and
pericentral (Dd) hepatocytes. One could cell sort these two different subsets of
hepatocytes and run ChIP analysis on E3 transgene for the presense of ROR or the Reverb proteins. Another approach, using mRNA-seq, could identify differential expression
of genes between periportal and pericental hepatocytes possibly elucidating novel factors
involved with zonal regualtion.
RGSe is not as well characterized compared to E3, but binding site analysis has
not identified a ROR binding site. Endogenous GS expression is slightly reduced in
ROR-/- livers suggesting other factors may be involved in its regulation. Based on these
observations, if RGSe mice were bred to ROR null mice, I would not predict any
transgene changes in activity with or without ROR. The nuclear receptor HNF4 seems
to have a greater impact on GS expression compared to data from ROR. HNF4
knockout livers increase GS expression into non-pericentral hepatocytes detected by
immunohistochemistry suggesting HNF represses GS in non-pericentral hepatocytes
[50]. Unfortunately, the binding sites identified and characterized in GS were not located
within the enhancer [211]. Through similar binding site analysis with TESS I have
identified a putative HNF4 binding site within RGSe. In vitro tests could be performed
first, co-transfecting increasing HNF4 with wildtype RGSe-pGL3 and HNF4 mutant
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RGSe to determine if this site was functional and responsive to HNF4. I predict, if
mutated, RGSe activity in vivo would increase into non-pericentral hepatocytes much like
that of the NR mutation in E3.
Our model for zonal regulation also includes these different factors, -catenin and
nuclear receptors exerting their function through an enhancer element. GS is not the only
zonal genes in which enhancers have been identified. More recently, four putative
enhancer elements were identified upstream of the OAT transcription start site. Cloning
each individual enhancer showed activity in the eye, gut, and kidney (J. Butler).
Unfortunately, the final putative enhancer was not found to have any liver activity (data
not shown). We are currently exploring other putative enhancer elements found within
RhBG and I predict one will recapitulate zonal activity. While our focus has been mainly
on pericental genes, not much is known about the zonal regulation of periportal genes.
PEPCK, as mentioned before, is regulated by many nutritional and hormonal signals [39],
but the factor to silence it in pericentral hepatocytes remains unknown. Linking the
promoter to a heterologous gene drives the expression to a zonal pattern much like that of
the endogenous gene. Therefore, I predict periportal genes are zonally regulated
primarily through the promoter. The PEPCK-Ld transgenic mice could then serve as a
model system to understanding periportal gene regulation.
Zhx2 and Cholesterol Homeostasis. Overall lipid homeostasis is important since
imbalance can lead to disease such as obesity, diabetes, atherosclerosis and NAFLD.
While the QTL study shows presence of Zhx2 causes susceptibility to an atherogenic diet
due to increased serum cholesterol and triglyceride levels, my data suggests it also
protects against liver damage. Liver damage introduces additional consequences for if it
becomes chronic, NAFLD can progress to cirrhosis which is known to promote the
development of HCC [186]. My data also validates gene expression changes, similar to
those observed in the Lusis microarray, identifying novel Zhx2 targets. Lpl, Cyp8B1 and
Elovl3 fall within this category, but have slightly different expression patterns based on
Zhx2 status and type of diet. While the mechanism for how Zhx2 regulates its target
genes remains unknown studying additional targets provides new models for
understanding the mechanism. The postnatal repression of AFP by Zhx2 occurs in the
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250 proximal promoter therefore, the prediction is these new target genes would also be
regulated through their promoters. PCR amplified promoters from each of these genes
could be placed in the pGL3 enhancer construct and co-transfected in hepatoma cell lines
along with a Zhx2 expression plasmid. I would expect constructs with Lpl and Cyp8B1
promoters would have reduced luciferase levels with the addition of Zhx2. Transfection
studies with AFP and Zhx2 have proven difficult since the 10 to 20-fold difference seen
between BALB/cJ and other strains is not recapitulated with this system. The maximum
reduction Zhx2 exerts at the 250 bp AFP promoter is 2-fold. Examining the Elovl3
promoter would provide a better model system since addition of Zhx2 would have an
opposite effect, causing an increase in luciferase levels. If all of the promoters respond,
gradual deletions of promoter regions could localize elements responsive to Zhx2 that can
then be compared amongst all the target genes to determine a consensus sequence.
Throughout the years no binding of Zhx2 to the AFP promoter has been detected
suggesting a post-transciptional regulation by Zhx2. Unspliced AFP is found in the
cytoplasm in the presense of Zhx2 (Turcios, L and Peterson, M. unpub data). To see if
this occurs in the new targets several primers can be designed to monitor inclusion of
introns in the mRNA.
Damage occurs in the liver multiple ways due to its encounter with many
molecules and substances on a daily basis. Though the mechanisms of hepatocyte stress
and cell death may differ, HCC development is a common end result of chronic damage.
For NAFLD, in particular, chronic inflammation is not the only causative source of
hepatic injury. In my study, I have shown serum ALT and AFP are induced in BALB/cJ
during a high fat feeding. I predict based on these parameters that there is increased cell
death during the high fat feeding, the most occurring in BALB/cJ livers, which can be
quantified using Tunel staining of paraffin embedded sections. Lipids are known to cause
damage through stress and metabolism. Lipid oxidation of fatty acids can produce
reactive-oxygen species (ROS) that lead to cell death [212]. Since BALB/cJ mice seem to
accumulate more lipids based on Oil Red O, I would hypothesize ROS levels are
dramatically increased compared to BALB/c and BALB/cJ+Zhx2 during high fat feeding.
Liver damage activates stellate cells which deposit collagen as a regeneration mechanism.
Years ago QTL mapping of BALB/cJ and A/J mice located a site on mouse chromosome
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15 associated with fibrosis, a similar region to the location of Zhx2. BALB/cJ mice
exhibit more severe fibrosis which could be occurring in this diet study [213]. Collagen
deposition can be easily detected and quantified using staining techniques on paraffinembedded sections. I would predict that BALB/cJ hepatic collagen levels would be
higher than BALB/c livers on the high fat chow. This too may also be due to Zhx2
expression within stellate cells. Therefore, I would not predict a difference in collagen
levels between BALB/cJ and BALB/cJ+Zhx2 since the transgene is only expressed in
hepatocytes.
The liver is not the only tissue found important for the progression of metabolic
diseases. Macrophages are a major culprit for they develop into foam cells when
phagocytosing lipids, which adds to atherosclerotic plaques [214]. Dysregulation of fat
storage or increased inflammation occurring in the adipose tissue has major implications
in the metabolic diseases [215]. Due to its ubiquitous expression profile [96] and
implications in other diseases [101, 106, 216], it is possible the Zhx2 may be playing
regulatory roles in these other tissues that have not yet been identified. We have recently
obtained Zhx2 floxed mice from the KnockOut Mouse Project (KOMP) in which their
targeting vector inserted loxP sites flanking exon 3, the coding region of Zhx2. These
mice can then breed to mice containing cre-recombinase driven by various promoters to
delete Zhx2 in a tissue specific manner. Based on our laboratory’s interests we would
first knock-out Zhx2 in hepatocytes. If these mice are placed on an atherogenic diet I
would predict a phenotype similar to that of BALB/cJ; lower serum lipid levels compared
to wildtype animals, low incidence of atherosclerotic plaques, increased serum ALT and
AFP mRNA levels. Tissue specific Zhx2 deletion could elucidate Zhx2 regulatory roles
during high fat feeding in other metabolic tissues mentioned above. Zhx2 knockout may
in fact provide a better model since BALB/cJ mice are a knock-down of Zhx2 in protein
and mRNA levels compared to either BALB/c or BALB/cJ+Zhx2.

Copyright© Erica Leigh Clinkenbeard
98

References
1.
2.
3.
4.
5.
6.
7.
8.
9.

10.

11.
12.
13.
14.

Gebhardt, R., Metabolic zonation of the liver: regulation and implications for
liver function. Pharmacol Ther, 1992. 53(3): p. 275-354.
Spear, B.T., L. Jin, S. Ramasamy, and A. Dobierzewska, Transcriptional control
in the mammalian liver: liver development, perinatal repression, and zonal gene
regulation. Cell Mol Life Sci, 2006. 63(24): p. 2922-38.
Houssaint, E., Differentiation of the mouse hepatic primordium. I. An analysis of
tissue interactions in hepatocyte differentiation. Cell Differ, 1980. 9(5): p. 26979.
Medlock, E.S. and J.L. Haar, The liver hemopoietic environment: I. Developing
hepatocytes and their role in fetal hemopoiesis. Anat Rec, 1983. 207(1): p. 31-41.
Suzuki, K., M. Tanaka, N. Watanabe, S. Saito, H. Nonaka, and A. Miyajima, p75
Neurotrophin receptor is a marker for precursors of stellate cells and portal
fibroblasts in mouse fetal liver. Gastroenterology, 2008. 135(1): p. 270-281 e3.
Bort, R., M. Signore, K. Tremblay, J.P. Martinez Barbera, and K.S. Zaret, Hex
homeobox gene controls the transition of the endoderm to a pseudostratified, cell
emergent epithelium for liver bud development. Dev Biol, 2006. 290(1): p. 44-56.
Ludtke, T.H., V.M. Christoffels, M. Petry, and A. Kispert, Tbx3 promotes liver
bud expansion during mouse development by suppression of cholangiocyte
differentiation. Hepatology, 2009. 49(3): p. 969-78.
Apte, U., G. Zeng, M.D. Thompson, P. Muller, A. Micsenyi, B. Cieply, K.H.
Kaestner, and S.P. Monga, beta-Catenin is critical for early postnatal liver
growth. Am J Physiol Gastrointest Liver Physiol, 2007. 292(6): p. G1578-85.
Tan, X., Y. Yuan, G. Zeng, U. Apte, M.D. Thompson, B. Cieply, D.B. Stolz, G.K.
Michalopoulos, K.H. Kaestner, and S.P. Monga, Beta-catenin deletion in
hepatoblasts disrupts hepatic morphogenesis and survival during mouse
development. Hepatology, 2008. 47(5): p. 1667-79.
Monga, S.P., H.K. Monga, X. Tan, K. Mule, P. Pediaditakis, and G.K.
Michalopoulos, Beta-catenin antisense studies in embryonic liver cultures: role in
proliferation, apoptosis, and lineage specification. Gastroenterology, 2003.
124(1): p. 202-16.
Lemaigre, F.P., Development of the biliary tract. Mech Dev, 2003. 120(1): p. 817.
Raiha, N.C. and J. Suihkonen, Factors influencing the development of ureasynthesizing enzymes in rat liver. Biochem J, 1968. 107(6): p. 793-7.
Greengard, O., The hormonal regulation of enzymes in penatal and postnatal rat
liver. Effects of adenosine 3',5'-(cyclic)-monophosphate. Biochem J, 1969.
115(1): p. 19-24.
Haridass, D., Q. Yuan, P.D. Becker, T. Cantz, M. Iken, M. Rothe, N. Narain, M.
Bock, M. Norder, N. Legrand, H. Wedemeyer, K. Weijer, H. Spits, M.P. Manns,
J. Cai, H. Deng, J.P. Di Santo, C.A. Guzman, and M. Ott, Repopulation
efficiencies of adult hepatocytes, fetal liver progenitor cells, and embryonic stem
cell-derived hepatic cells in albumin-promoter-enhancer urokinase-type
plasminogen activator mice. Am J Pathol, 2009. 175(4): p. 1483-92.
99

15.
16.
17.
18.

19.
20.
21.
22.
23.
24.
25.
26.
27.
28.
29.

Robison, W.G., Jr. and T. Kuwabara, Vitamin A storage and peroxisomes in
retinal pigment epithelium and liver. Invest Ophthalmol Vis Sci, 1977. 16(12): p.
1110-7.
Lukita-Atmadja, W. and Subowo, The stellate cells phenotypic transformation in
the CCl4- injured liver fibrosis of ICR mice: their desmin immunoreactivity and
vitamin A storage. Kobe J Med Sci, 1993. 39(1): p. 15-33.
Friedman, S.L., Hepatic stellate cells: protean, multifunctional, and enigmatic
cells of the liver. Physiol Rev, 2008. 88(1): p. 125-72.
Shen, K., W. Chang, X. Gao, H. Wang, W. Niu, L. Song, and X. Qin, Depletion
of activated hepatic stellate cell correlates with severe liver damage and
abnormal liver regeneration in acetaminophen-induced liver injury. Acta
Biochim Biophys Sin (Shanghai), 2011. 43(4): p. 307-15.
Crofton, R.W., M.M. Diesselhoff-den Dulk, and R. van Furth, The origin,
kinetics, and characteristics of the Kupffer cells in the normal steady state. J Exp
Med, 1978. 148(1): p. 1-17.
Laskin, D.L., L. Chen, P.A. Hankey, and J.D. Laskin, Role of STK in mouse liver
macrophage and endothelial cell responsiveness during acute endotoxemia. J
Leukoc Biol, 2010. 88(2): p. 373-82.
Lee, S.J., S.Y. Park, M.Y. Jung, S.M. Bae, and I.S. Kim, Mechanism for
phosphatidylserine-dependent erythrophagocytosis in mouse liver. Blood, 2011.
117(19): p. 5215-23.
Grisham, J.W., Cell types in long-term propagable cultures of rat liver. Ann N Y
Acad Sci, 1980. 349: p. 128-37.
Kano, J., M. Noguchi, M. Kodama, and T. Tokiwa, The in vitro differentiating
capacity of nonparenchymal epithelial cells derived from adult porcine livers. Am
J Pathol, 2000. 156(6): p. 2033-43.
Fujiyoshi, M. and M. Ozaki, Molecular mechanisms of liver regeneration and
protection for treatment of liver dysfunction and diseases. J Hepatobiliary
Pancreat Sci, 2011. 18(1): p. 13-22.
Darwiche, H., S.H. Oh, N.C. Steiger-Luther, J.M. Williams, D.G. Pintilie, T.D.
Shupe, and B.E. Petersen, Inhibition of Notch signaling affects hepatic oval cell
response in rat model of 2AAF-PH. Hepat Med, 2011. 3: p. 89-98.
Bouwens, L., P. De Bleser, K. Vanderkerken, B. Geerts, and E. Wisse, Liver cell
heterogeneity: functions of non-parenchymal cells. Enzyme, 1992. 46(1-3): p.
155-68.
Elvevold, K., B. Smedsrod, and I. Martinez, The liver sinusoidal endothelial cell:
a cell type of controversial and confusing identity. Am J Physiol Gastrointest
Liver Physiol, 2008. 294(2): p. G391-400.
Everson, G.T., M.J. Lawson, C. McKinley, R. Showalter, and F. Kern, Jr.,
Gallbladder and small intestinal regulation of biliary lipid secretion during
intraduodenal infusion of standard stimuli. J Clin Invest, 1983. 71(3): p. 596-603.
Wisse, E., F. Braet, D. Luo, R. De Zanger, D. Jans, E. Crabbe, and A. Vermoesen,
Structure and function of sinusoidal lining cells in the liver. Toxicol Pathol, 1996.
24(1): p. 100-11.

100

30.
31.
32.
33.

34.
35.

36.

37.

38.
39.

40.
41.
42.
43.
44.

Jungermann, K., Dynamics of zonal hepatocyte heterogeneity. Perinatal
development and adaptive alterations during regeneration after partial
hepatectomy, starvation and diabetes. Acta Histochem Suppl, 1986. 32: p. 89-98.
Jungermann, K. and N. Katz, Functional specialization of different hepatocyte
populations. Physiol Rev, 1989. 69(3): p. 708-64.
Gebhardt, R. and D. Mecke, Heterogeneous distribution of glutamine synthetase
among rat liver parenchymal cells in situ and in primary culture. EMBO J, 1983.
2(4): p. 567-70.
van Straaten, H.W., Y. He, M.M. van Duist, W.T. Labruyere, J.L. Vermeulen, P.J.
van Dijk, J.M. Ruijter, W.H. Lamers, and T.B. Hakvoort, Cellular concentrations
of glutamine synthetase in murine organs. Biochem Cell Biol, 2006. 84(2): p.
215-31.
Gaasbeek Janzen, J.W., R. Gebhardt, G.H. ten Voorde, W.H. Lamers, R. Charles,
and A.F. Moorman, Heterogeneous distribution of glutamine synthetase during
rat liver development. J Histochem Cytochem, 1987. 35(1): p. 49-54.
Gaasbeek Janzen, J.W., W.H. Lamers, A.F. Moorman, A. de Graaf, J.A. Los, and
R. Charles, Immunohistochemical localization of carbamoyl-phosphate synthetase
(ammonia) in adult rat liver; evidence for a heterogeneous distribution. J
Histochem Cytochem, 1984. 32(6): p. 557-64.
Benhamouche, S., T. Decaens, C. Godard, R. Chambrey, D.S. Rickman, C.
Moinard, M. Vasseur-Cognet, C.J. Kuo, A. Kahn, C. Perret, and S. Colnot, Apc
tumor suppressor gene is the "zonation-keeper" of mouse liver. Dev Cell, 2006.
10(6): p. 759-70.
Pekkala, S., A.I. Martinez, B. Barcelona, I. Yefimenko, U. Finckh, V. Rubio, and
J. Cervera, Understanding carbamoyl-phosphate synthetase I (CPS1) deficiency
by using expression studies and structure-based analysis. Hum Mutat, 2010.
31(7): p. 801-8.
Jungermann, K., Functional heterogeneity of periportal and perivenous
hepatocytes. Enzyme, 1986. 35(3): p. 161-80.
Wynshaw-Boris, A., J.M. Short, D.S. Loose, and R.W. Hanson, Characterization
of the phosphoenolpyruvate carboxykinase (GTP) promoter-regulatory region. I.
Multiple hormone regulatory elements and the effects of enhancers. J Biol Chem,
1986. 261(21): p. 9714-20.
Teutsch, H.F., Quantitative determination of G6Pase activity in histochemically
defined zones of the liver acinus. Histochemistry, 1978. 58(4): p. 281-8.
Jungermann, K., R. Heilbronn, N. Katz, and D. Sasse, The glucose/glucose-6phosphate cycle in the periportal and perivenous zone of rat liver. Eur J Biochem,
1982. 123(2): p. 429-36.
Buhler, R., K.O. Lindros, A. Nordling, I. Johansson, and M. Ingelman-Sundberg,
Zonation of cytochrome P450 isozyme expression and induction in rat liver. Eur J
Biochem, 1992. 204(1): p. 407-12.
Chianale, J., C. Dvorak, M. May, and J.J. Gumucio, Heterogeneous expression of
phenobarbital-inducible cytochrome P-450 genes within the hepatic acinus in the
rat. Hepatology, 1986. 6(5): p. 945-51.
Jungermann, K. and T. Kietzmann, Oxygen: modulator of metabolic zonation and
disease of the liver. Hepatology, 2000. 31(2): p. 255-60.
101

45.

46.

47.

48.
49.

50.

51.
52.
53.
54.

55.
56.
57.

Fahrner, J., W.T. Labruyere, C. Gaunitz, A.F. Moorman, R. Gebhardt, and W.H.
Lamers, Identification and functional characterization of regulatory elements of
the glutamine synthetase gene from rat liver. Eur J Biochem, 1993. 213(3): p.
1067-73.
Wynshaw-Boris, A., T.G. Lugo, J.M. Short, R.E. Fournier, and R.W. Hanson,
Identification of a cAMP regulatory region in the gene for rat cytosolic
phosphoenolpyruvate carboxykinase (GTP). Use of chimeric genes transfected
into hepatoma cells. J Biol Chem, 1984. 259(19): p. 12161-9.
Sasaki, K., T.P. Cripe, S.R. Koch, T.L. Andreone, D.D. Petersen, E.G. Beale, and
D.K. Granner, Multihormonal regulation of phosphoenolpyruvate carboxykinase
gene transcription. The dominant role of insulin. J Biol Chem, 1984. 259(24): p.
15242-51.
Lindros, K.O., T. Oinonen, J. Issakainen, P. Nagy, and S.S. Thorgeirsson, Zonal
distribution of transcripts of four hepatic transcription factors in the mature rat
liver. Cell Biol Toxicol, 1997. 13(4-5): p. 257-62.
Santangelo, L., A. Marchetti, C. Cicchini, A. Conigliaro, B. Conti, C. Mancone,
J.A. Bonzo, F.J. Gonzalez, T. Alonzi, L. Amicone, and M. Tripodi, The stable
repression of mesenchymal program is required for hepatocyte identity: a novel
role for hepatocyte nuclear factor 4alpha. Hepatology, 2011. 53(6): p. 2063-74.
Stanulovic, V.S., I. Kyrmizi, M. Kruithof-de Julio, M. Hoogenkamp, J.L.
Vermeulen, J.M. Ruijter, I. Talianidis, T.B. Hakvoort, and W.H. Lamers, Hepatic
HNF4alpha deficiency induces periportal expression of glutamine synthetase and
other pericentral enzymes. Hepatology, 2007. 45(2): p. 433-44.
Yin, L., H. Ma, X. Ge, P.A. Edwards, and Y. Zhang, Hepatic hepatocyte nuclear
factor 4alpha is essential for maintaining triglyceride and cholesterol
homeostasis. Arterioscler Thromb Vasc Biol, 2011. 31(2): p. 328-36.
Lu, H., F.J. Gonzalez, and C. Klaassen, Alterations in hepatic mRNA expression
of phase II enzymes and xenobiotic transporters after targeted disruption of
hepatocyte nuclear factor 4 alpha. Toxicol Sci, 2010. 118(2): p. 380-90.
Behrens, J., J.P. von Kries, M. Kuhl, L. Bruhn, D. Wedlich, R. Grosschedl, and
W. Birchmeier, Functional interaction of beta-catenin with the transcription
factor LEF-1. Nature, 1996. 382(6592): p. 638-42.
McCrea, P.D. and B.M. Gumbiner, Purification of a 92-kDa cytoplasmic protein
tightly associated with the cell-cell adhesion molecule E-cadherin (uvomorulin).
Characterization and extractability of the protein complex from the cell
cytostructure. J Biol Chem, 1991. 266(7): p. 4514-20.
Aberle, H., S. Butz, J. Stappert, H. Weissig, R. Kemler, and H. Hoschuetzky,
Assembly of the cadherin-catenin complex in vitro with recombinant proteins. J
Cell Sci, 1994. 107 ( Pt 12): p. 3655-63.
Aberle, H., A. Bauer, J. Stappert, A. Kispert, and R. Kemler, beta-catenin is a
target for the ubiquitin-proteasome pathway. EMBO J, 1997. 16(13): p. 3797804.
Peifer, M., D. Sweeton, M. Casey, and E. Wieschaus, wingless signal and Zestewhite 3 kinase trigger opposing changes in the intracellular distribution of
Armadillo. Development, 1994. 120(2): p. 369-80.

102

58.
59.
60.
61.
62.
63.
64.
65.
66.
67.
68.

69.
70.
71.
72.

Cook, D., M.J. Fry, K. Hughes, R. Sumathipala, J.R. Woodgett, and T.C. Dale,
Wingless inactivates glycogen synthase kinase-3 via an intracellular signalling
pathway which involves a protein kinase C. EMBO J, 1996. 15(17): p. 4526-36.
Bhanot, P., M. Brink, C.H. Samos, J.C. Hsieh, Y. Wang, J.P. Macke, D. Andrew,
J. Nathans, and R. Nusse, A new member of the frizzled family from Drosophila
functions as a Wingless receptor. Nature, 1996. 382(6588): p. 225-30.
Clevers, H. and M. van de Wetering, TCF/LEF factor earn their wings. Trends
Genet, 1997. 13(12): p. 485-9.
Jennings, B.H. and D. Ish-Horowicz, The Groucho/TLE/Grg family of
transcriptional co-repressors. Genome Biol, 2008. 9(1): p. 205.
Sun, Y., F.T. Kolligs, M.O. Hottiger, R. Mosavin, E.R. Fearon, and G.J. Nabel,
Regulation of beta -catenin transformation by the p300 transcriptional
coactivator. Proc Natl Acad Sci U S A, 2000. 97(23): p. 12613-8.
Cheng, H., H. Liang, Y. Qin, and Y. Liu, Nuclear beta-catenin overexpression in
metastatic sentinel lymph node is associated with synchronous liver metastasis in
colorectal cancer. Diagn Pathol, 2011. 6(1): p. 109.
Shtutman, M., J. Zhurinsky, I. Simcha, C. Albanese, M. D'Amico, R. Pestell, and
A. Ben-Ze'ev, The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway.
Proc Natl Acad Sci U S A, 1999. 96(10): p. 5522-7.
McLin, V.A., S.A. Rankin, and A.M. Zorn, Repression of Wnt/beta-catenin
signaling in the anterior endoderm is essential for liver and pancreas
development. Development, 2007. 134(12): p. 2207-17.
Peifer, M., The product of the Drosophila segment polarity gene armadillo is part
of a multi-protein complex resembling the vertebrate adherens junction. J Cell
Sci, 1993. 105 ( Pt 4): p. 993-1000.
Mazumdar, J., W.T. O'Brien, R.S. Johnson, J.C. LaManna, J.C. Chavez, P.S.
Klein, and M.C. Simon, O2 regulates stem cells through Wnt/beta-catenin
signalling. Nat Cell Biol, 2010. 12(10): p. 1007-13.
Kim, J.A., Y.J. Kang, G. Park, M. Kim, Y.O. Park, H. Kim, S.H. Leem, I.S. Chu,
J.S. Lee, E.H. Jho, and I.H. Oh, Identification of a stroma-mediated Wnt/betacatenin signal promoting self-renewal of hematopoietic stem cells in the stem cell
niche. Stem Cells, 2009. 27(6): p. 1318-29.
Monga, S.P., P. Pediaditakis, K. Mule, D.B. Stolz, and G.K. Michalopoulos,
Changes in WNT/beta-catenin pathway during regulated growth in rat liver
regeneration. Hepatology, 2001. 33(5): p. 1098-109.
Sekine, S., P.J. Gutierrez, B.Y. Lan, S. Feng, and M. Hebrok, Liver-specific loss
of beta-catenin results in delayed hepatocyte proliferation after partial
hepatectomy. Hepatology, 2007. 45(2): p. 361-8.
Tan, X., J. Behari, B. Cieply, G.K. Michalopoulos, and S.P. Monga, Conditional
deletion of beta-catenin reveals its role in liver growth and regeneration.
Gastroenterology, 2006. 131(5): p. 1561-72.
de La Coste, A., B. Romagnolo, P. Billuart, C.A. Renard, M.A. Buendia, O.
Soubrane, M. Fabre, J. Chelly, C. Beldjord, A. Kahn, and C. Perret, Somatic
mutations of the beta-catenin gene are frequent in mouse and human
hepatocellular carcinomas. Proc Natl Acad Sci U S A, 1998. 95(15): p. 8847-51.

103

73.

74.
75.
76.
77.
78.
79.
80.
81.
82.
83.

84.
85.
86.

87.
88.

Miyaki, M., T. Iijima, J. Kimura, M. Yasuno, T. Mori, Y. Hayashi, M. Koike, N.
Shitara, T. Iwama, and T. Kuroki, Frequent mutation of beta-catenin and APC
genes in primary colorectal tumors from patients with hereditary nonpolyposis
colorectal cancer. Cancer Res, 1999. 59(18): p. 4506-9.
Tetsu, O. and F. McCormick, Beta-catenin regulates expression of cyclin D1 in
colon carcinoma cells. Nature, 1999. 398(6726): p. 422-6.
Cadoret, A., C. Ovejero, B. Terris, E. Souil, L. Levy, W.H. Lamers, J. Kitajewski,
A. Kahn, and C. Perret, New targets of beta-catenin signaling in the liver are
involved in the glutamine metabolism. Oncogene, 2002. 21(54): p. 8293-301.
Deutsch, H.F., Chemistry and biology of alpha-fetoprotein. Adv Cancer Res,
1991. 56: p. 253-312.
Chen, H., J.O. Egan, and J.F. Chiu, Regulation and activities of alpha-fetoprotein.
Crit Rev Eukaryot Gene Expr, 1997. 7(1-2): p. 11-41.
Murray, M.J. and J.C. Nicholson, alpha-Fetoprotein. Arch Dis Child Educ Pract
Ed, 2011. 96(4): p. 141-7.
Bredaki, F.E., D. Wright, P. Matos, A. Syngelaki, and K.H. Nicolaides, FirstTrimester Screening for Trisomy 21 Using Alpha-Fetoprotein. Fetal Diagn Ther,
2011.
Tilghman, S.M. and A. Belayew, Transcriptional control of the murine
albumin/alpha-fetoprotein locus during development. Proc Natl Acad Sci U S A,
1982. 79(17): p. 5254-7.
Chen, M., P. Sun, X.Y. Liu, D. Dong, J. Du, L. Gu, and Y.B. Ge, alphafetoprotein involvement during glucocorticoid-induced precocious maturation in
rat colon. World J Gastroenterol, 2011. 17(24): p. 2933-40.
Pintilie, D.G., T.D. Shupe, S.H. Oh, S.V. Salganik, H. Darwiche, and B.E.
Petersen, Hepatic stellate cells' involvement in progenitor-mediated liver
regeneration. Lab Invest, 2010. 90(8): p. 1199-208.
Yau, T., T.J. Yao, P. Chan, H. Wong, R. Pang, S.T. Fan, and R.T. Poon, The
significance of early alpha-fetoprotein level changes in predicting clinical and
survival benefits in advanced hepatocellular carcinoma patients receiving
sorafenib. Oncologist, 2011. 16(9): p. 1270-9.
Belanger, L., S. Roy, and D. Allard, New albumin gene 3' adjacent to the alpha 1fetoprotein locus. J Biol Chem, 1994. 269(8): p. 5481-4.
Cooke, N.E. and E.V. David, Serum vitamin D-binding protein is a third member
of the albumin and alpha fetoprotein gene family. J Clin Invest, 1985. 76(6): p.
2420-4.
Lichenstein, H.S., D.E. Lyons, M.M. Wurfel, D.A. Johnson, M.D. McGinley, J.C.
Leidli, D.B. Trollinger, J.P. Mayer, S.D. Wright, and M.M. Zukowski, Afamin is
a new member of the albumin, alpha-fetoprotein, and vitamin D-binding protein
gene family. J Biol Chem, 1994. 269(27): p. 18149-54.
Godbout, R., R. Ingram, and S.M. Tilghman, Multiple regulatory elements in the
intergenic region between the alpha-fetoprotein and albumin genes. Mol Cell
Biol, 1986. 6(2): p. 477-87.
Godbout, R., R.S. Ingram, and S.M. Tilghman, Fine-structure mapping of the
three mouse alpha-fetoprotein gene enhancers. Mol Cell Biol, 1988. 8(3): p.
1169-78.
104

89.
90.
91.

92.
93.
94.
95.
96.

97.
98.
99.

100.
101.
102.
103.

Ramesh, T.M., A.W. Ellis, and B.T. Spear, Individual mouse alpha-fetoprotein
enhancer elements exhibit different patterns of tissue-specific and hepatic
position-dependent activities. Mol Cell Biol, 1995. 15(9): p. 4947-55.
Peyton, D.K., T. Ramesh, and B.T. Spear, Position-dependent activity of alpha fetoprotein enhancer element III in the adult liver is due to negative regulation.
Proc Natl Acad Sci U S A, 2000. 97(20): p. 10890-4.
McVey, J.H., K. Michaelides, L.P. Hansen, M. Ferguson-Smith, S. Tilghman, R.
Krumlauf, and E.G. Tuddenham, A G-->A substitution in an HNF I binding site in
the human alpha-fetoprotein gene is associated with hereditary persistence of
alpha-fetoprotein (HPAFP). Hum Mol Genet, 1993. 2(4): p. 379-84.
Olsson, M., G. Lindahl, and E. Ruoslahti, Genetic control of alpha-fetoprotein
synthesis in the mouse. J Exp Med, 1977. 145(4): p. 819-27.
Belayew, A. and S.M. Tilghman, Genetic analysis of alpha-fetoprotein synthesis
in mice. Mol Cell Biol, 1982. 2(11): p. 1427-35.
Camper, S.A. and S.M. Tilghman, Postnatal repression of the alpha-fetoprotein
gene is enhancer independent. Genes Dev, 1989. 3(4): p. 537-46.
Peyton, D.K., M.C. Huang, M.A. Giglia, N.K. Hughes, and B.T. Spear, The
alpha-fetoprotein promoter is the target of Afr1-mediated postnatal repression.
Genomics, 2000. 63(2): p. 173-80.
Perincheri, S., R.W. Dingle, M.L. Peterson, and B.T. Spear, Hereditary
persistence of alpha-fetoprotein and H19 expression in liver of BALB/cJ mice is
due to a retrovirus insertion in the Zhx2 gene. Proc Natl Acad Sci U S A, 2005.
102(2): p. 396-401.
Perincheri, S., D.K. Peyton, M. Glenn, M.L. Peterson, and B.T. Spear,
Characterization of the ETnII-alpha endogenous retroviral element in the
BALB/cJ Zhx2 ( Afr1 ) allele. Mamm Genome, 2008. 19(1): p. 26-31.
Kawata, H., K. Yamada, Z. Shou, T. Mizutani, and K. Miyamoto, The mouse
zinc-fingers and homeoboxes (ZHX) family; ZHX2 forms a heterodimer with
ZHX3. Gene, 2003. 323: p. 133-40.
Kawata, H., K. Yamada, Z. Shou, T. Mizutani, T. Yazawa, M. Yoshino, T.
Sekiguchi, T. Kajitani, and K. Miyamoto, Zinc-fingers and homeoboxes (ZHX) 2,
a novel member of the ZHX family, functions as a transcriptional repressor.
Biochem J, 2003. 373(Pt 3): p. 747-57.
Lv, Z., M. Zhang, J. Bi, F. Xu, S. Hu, and J. Wen, Promoter hypermethylation of
a novel gene, ZHX2, in hepatocellular carcinoma. Am J Clin Pathol, 2006.
125(5): p. 740-6.
Yamada, K., H. Ogata-Kawata, K. Matsuura, N. Kagawa, K. Takagi, K. Asano,
A. Haneishi, and K. Miyamoto, ZHX2 and ZHX3 repress cancer markers in
normal hepatocytes. Front Biosci, 2009. 14: p. 3724-32.
De Andrade, T., L. Moreira, A. Duarte, C. Lanaro, D. De Albuquerque, S. Saad,
and F. Costa, Expression of new red cell-related genes in erythroid
differentiation. Biochem Genet, 2010. 48(1-2): p. 164-71.
Liu, G., L.C. Clement, Y.S. Kanwar, C. Avila-Casado, and S.S. Chugh, ZHX
proteins regulate podocyte gene expression during the development of nephrotic
syndrome. J Biol Chem, 2006. 281(51): p. 39681-92.

105

104.

105.

106.

107.

108.
109.
110.
111.

112.

113.
114.
115.

116.

Philippe, A., S. Weber, E.L. Esquivel, C. Houbron, G. Hamard, J. Ratelade, W.
Kriz, F. Schaefer, M.C. Gubler, and C. Antignac, A missense mutation in podocin
leads to early and severe renal disease in mice. Kidney Int, 2008. 73(9): p. 103847.
Hystad, M.E., J.H. Myklebust, T.H. Bo, E.A. Sivertsen, E. Rian, L. Forfang, E.
Munthe, A. Rosenwald, M. Chiorazzi, I. Jonassen, L.M. Staudt, and E.B.
Smeland, Characterization of early stages of human B cell development by gene
expression profiling. J Immunol, 2007. 179(6): p. 3662-71.
Armellini, A., M.E. Sarasquete, R. Garcia-Sanz, M.C. Chillon, A. Balanzategui,
M. Alcoceba, M. Fuertes, R. Lopez, J.M. Hernandez, J. Fernandez-Calvo, M.
Sierra, M. Megido, A. Orfao, N.C. Gutierrez, M. Gonzalez, and J.F. San Miguel,
Low expression of ZHX2, but not RCBTB2 or RAN, is associated with poor
outcome in multiple myeloma. Br J Haematol, 2008. 141(2): p. 212-5.
Schroeder, F., H. Huang, A.L. McIntosh, B.P. Atshaves, G.G. Martin, and A.B.
Kier, Caveolin, sterol carrier protein-2, membrane cholesterol-rich
microdomains and intracellular cholesterol trafficking. Subcell Biochem, 2010.
51: p. 279-318.
Shammaa, M.H. and I. Somerville, Bile Acid and Cholesterol Metabolism. J Med
Liban, 1963. 16: p. 75-88.
Boyd, G.S., Hormones and cholesterol metabolism. Biochem Soc Symp, 1963.
24: p. 79-98.
Kohan, A., S. Yoder, and P. Tso, Lymphatics in intestinal transport of nutrients
and gastrointestinal hormones. Ann N Y Acad Sci, 2010. 1207 Suppl 1: p. E4451.
Neufeld, E.B., A.T. Remaley, S.J. Demosky, J.A. Stonik, A.M. Cooney, M.
Comly, N.K. Dwyer, M. Zhang, J. Blanchette-Mackie, S. Santamarina-Fojo, and
H.B. Brewer, Jr., Cellular localization and trafficking of the human ABCA1
transporter. J Biol Chem, 2001. 276(29): p. 27584-90.
Foretz, M., C. Guichard, P. Ferre, and F. Foufelle, Sterol regulatory element
binding protein-1c is a major mediator of insulin action on the hepatic expression
of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A, 1999.
96(22): p. 12737-42.
Hua, X., A. Nohturfft, J.L. Goldstein, and M.S. Brown, Sterol resistance in CHO
cells traced to point mutation in SREBP cleavage-activating protein. Cell, 1996.
87(3): p. 415-26.
Wang, X., R. Sato, M.S. Brown, X. Hua, and J.L. Goldstein, SREBP-1, a
membrane-bound transcription factor released by sterol-regulated proteolysis.
Cell, 1994. 77(1): p. 53-62.
Pai, J.T., O. Guryev, M.S. Brown, and J.L. Goldstein, Differential stimulation of
cholesterol and unsaturated fatty acid biosynthesis in cells expressing individual
nuclear sterol regulatory element-binding proteins. J Biol Chem, 1998. 273(40):
p. 26138-48.
Chirieac, D.V., H.L. Collins, J. Cianci, J.D. Sparks, and C.E. Sparks, Altered
triglyceride-rich lipoprotein production in Zucker diabetic fatty rats. Am J
Physiol Endocrinol Metab, 2004. 287(1): p. E42-9.

106

117.

118.

119.
120.
121.

122.

123.
124.
125.
126.
127.
128.
129.
130.
131.
132.
133.

Pandak, W.M., C. Schwarz, P.B. Hylemon, D. Mallonee, K. Valerie, D.M.
Heuman, R.A. Fisher, K. Redford, and Z.R. Vlahcevic, Effects of CYP7A1
overexpression on cholesterol and bile acid homeostasis. Am J Physiol
Gastrointest Liver Physiol, 2001. 281(4): p. G878-89.
Plump, A.S., J.D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J.G. Verstuyft,
E.M. Rubin, and J.L. Breslow, Severe hypercholesterolemia and atherosclerosis
in apolipoprotein E-deficient mice created by homologous recombination in ES
cells. Cell, 1992. 71(2): p. 343-53.
Lennernas, H. and G. Fager, Pharmacodynamics and pharmacokinetics of the
HMG-CoA reductase inhibitors. Similarities and differences. Clin Pharmacokinet,
1997. 32(5): p. 403-25.
Shepherd, J., Mechanism of action of bile acid sequestrants and other lipidlowering drugs. Cardiology, 1989. 76 Suppl 1: p. 65-71; discussion 71-4.
Wang, X., P. Gargalovic, J. Wong, J.L. Gu, X. Wu, H. Qi, P. Wen, L. Xi, B. Tan,
R. Gogliotti, L.W. Castellani, A. Chatterjee, and A.J. Lusis, Hyplip2, a new gene
for combined hyperlipidemia and increased atherosclerosis. Arterioscler Thromb
Vasc Biol, 2004. 24(10): p. 1928-34.
Gargalovic, P.S., A. Erbilgin, O. Kohannim, J. Pagnon, X. Wang, L. Castellani,
R. LeBoeuf, M.L. Peterson, B.T. Spear, and A.J. Lusis, Quantitative trait locus
mapping and identification of Zhx2 as a novel regulator of plasma lipid
metabolism. Circ Cardiovasc Genet, 2010. 3(1): p. 60-7.
Zorn, A.M., Liver development. 2008.
White, P. and N. Cooke, The multifunctional properties and characteristics of
vitamin D-binding protein. Trends Endocrinol Metab, 2000. 11(8): p. 320-7.
Moon, R.T., A.D. Kohn, G.V. De Ferrari, and A. Kaykas, WNT and beta-catenin
signalling: diseases and therapies. Nat Rev Genet, 2004. 5(9): p. 691-701.
Willert, K. and R. Nusse, Beta-catenin: a key mediator of Wnt signaling. Curr
Opin Genet Dev, 1998. 8(1): p. 95-102.
Sekine, S., B.Y. Lan, M. Bedolli, S. Feng, and M. Hebrok, Liver-specific loss of
beta-catenin blocks glutamine synthesis pathway activity and cytochrome p450
expression in mice. Hepatology, 2006. 43(4): p. 817-25.
Burke, Z.D., K.R. Reed, T.J. Phesse, O.J. Sansom, A.R. Clarke, and D. Tosh,
Liver zonation occurs through a beta-catenin-dependent, c-Myc-independent
mechanism. Gastroenterology, 2009. 136(7): p. 2316-2324 e1-3.
Eastman, Q. and R. Grosschedl, Regulation of LEF-1/TCF transcription factors
by Wnt and other signals. Curr Opin Cell Biol, 1999. 11(2): p. 233-40.
Postic, C. and M.A. Magnuson, DNA excision in liver by an albumin-Cre
transgene occurs progressively with age. Genesis, 2000. 26(2): p. 149-50.
Groupp, E.R., N. Crawford, and J. Locker, Characterization of the distal alphafetoprotein enhancer, a strong, long distance, liver-specific activator. J Biol
Chem, 1994. 269(35): p. 22178-87.
Millonig, J.H., J.A. Emerson, J.M. Levorse, and S.M. Tilghman, Molecular
analysis of the distal enhancer of the mouse alpha-fetoprotein gene. Mol Cell
Biol, 1995. 15(7): p. 3848-56.
Bois-Joyeux, B., C. Chauvet, H. Nacer-Cherif, W. Bergeret, N. Mazure, V.
Giguere, V. Laudet, and J.L. Danan, Modulation of the far-upstream enhancer of
107

134.
135.
136.

137.
138.
139.

140.

141.

142.
143.
144.
145.
146.

the rat alpha-fetoprotein gene by members of the ROR alpha, Rev-erb alpha, and
Rev-erb beta groups of monomeric orphan nuclear receptors. DNA Cell Biol,
2000. 19(10): p. 589-99.
Shah, I., K. Houck, R.S. Judson, R.J. Kavlock, M.T. Martin, D.M. Reif, J.
Wambaugh, and D.J. Dix, Using nuclear receptor activity to stratify
hepatocarcinogens. PLoS One, 2011. 6(2): p. e14584.
Guo, G.L., S. Santamarina-Fojo, T.E. Akiyama, M.J. Amar, B.J. Paigen, B.
Brewer, Jr., and F.J. Gonzalez, Effects of FXR in foam-cell formation and
atherosclerosis development. Biochim Biophys Acta, 2006. 1761(12): p. 1401-9.
Benod, C., M.V. Vinogradova, N. Jouravel, G.E. Kim, R.J. Fletterick, and E.P.
Sablin, Nuclear receptor liver receptor homologue 1 (LRH-1) regulates
pancreatic cancer cell growth and proliferation. Proc Natl Acad Sci U S A, 2011.
108(41): p. 16927-31.
Strahle, U., G. Klock, and G. Schutz, A DNA sequence of 15 base pairs is
sufficient to mediate both glucocorticoid and progesterone induction of gene
expression. Proc Natl Acad Sci U S A, 1987. 84(22): p. 7871-5.
Ankenbauer, W., U. Strahle, and G. Schutz, Synergistic action of glucocorticoid
and estradiol responsive elements. Proc Natl Acad Sci U S A, 1988. 85(20): p.
7526-30.
Miyajima, N., R. Horiuchi, Y. Shibuya, S. Fukushige, K. Matsubara, K.
Toyoshima, and T. Yamamoto, Two erbA homologs encoding proteins with
different T3 binding capacities are transcribed from opposite DNA strands of the
same genetic locus. Cell, 1989. 57(1): p. 31-9.
Phelan, C.A., R.T. Gampe, Jr., M.H. Lambert, D.J. Parks, V. Montana, J. Bynum,
T.M. Broderick, X. Hu, S.P. Williams, R.T. Nolte, and M.A. Lazar, Structure of
Rev-erbalpha bound to N-CoR reveals a unique mechanism of nuclear receptorco-repressor interaction. Nat Struct Mol Biol, 2010. 17(7): p. 808-14.
Raghuram, S., K.R. Stayrook, P. Huang, P.M. Rogers, A.K. Nosie, D.B. McClure,
L.L. Burris, S. Khorasanizadeh, T.P. Burris, and F. Rastinejad, Identification of
heme as the ligand for the orphan nuclear receptors REV-ERBalpha and REVERBbeta. Nat Struct Mol Biol, 2007. 14(12): p. 1207-13.
Harding, H.P. and M.A. Lazar, The monomer-binding orphan receptor Rev-Erb
represses transcription as a dimer on a novel direct repeat. Mol Cell Biol, 1995.
15(9): p. 4791-802.
Ishizuka, T. and M.A. Lazar, The N-CoR/histone deacetylase 3 complex is
required for repression by thyroid hormone receptor. Mol Cell Biol, 2003.
23(15): p. 5122-31.
Yin, L. and M.A. Lazar, The orphan nuclear receptor Rev-erbalpha recruits the
N-CoR/histone deacetylase 3 corepressor to regulate the circadian Bmal1 gene.
Mol Endocrinol, 2005. 19(6): p. 1452-9.
Laitinen, S., C. Fontaine, J.C. Fruchart, and B. Staels, The role of the orphan
nuclear receptor Rev-Erb alpha in adipocyte differentiation and function.
Biochimie, 2005. 87(1): p. 21-5.
Preitner, N., F. Damiola, L. Lopez-Molina, J. Zakany, D. Duboule, U. Albrecht,
and U. Schibler, The orphan nuclear receptor REV-ERBalpha controls circadian

108

147.
148.
149.
150.
151.
152.
153.

154.
155.

156.

157.
158.
159.

transcription within the positive limb of the mammalian circadian oscillator. Cell,
2002. 110(2): p. 251-60.
Giguere, V., L.D. McBroom, and G. Flock, Determinants of target gene
specificity for ROR alpha 1: monomeric DNA binding by an orphan nuclear
receptor. Mol Cell Biol, 1995. 15(5): p. 2517-26.
Atkins, G.B., X. Hu, M.G. Guenther, C. Rachez, L.P. Freedman, and M.A. Lazar,
Coactivators for the orphan nuclear receptor RORalpha. Mol Endocrinol, 1999.
13(9): p. 1550-7.
Forman, B.M., J. Chen, B. Blumberg, S.A. Kliewer, R. Henshaw, E.S. Ong, and
R.M. Evans, Cross-talk among ROR alpha 1 and the Rev-erb family of orphan
nuclear receptors. Mol Endocrinol, 1994. 8(9): p. 1253-61.
Matysiak-Scholze, U. and M. Nehls, The structural integrity of ROR alpha
isoforms is mutated in staggerer mice: cerebellar coexpression of ROR alpha1
and ROR alpha4. Genomics, 1997. 43(1): p. 78-84.
Guillaumond, F., H. Dardente, V. Giguere, and N. Cermakian, Differential
control of Bmal1 circadian transcription by REV-ERB and ROR nuclear
receptors. J Biol Rhythms, 2005. 20(5): p. 391-403.
Amaral, I.P. and I.A. Johnston, Circadian expression of clock and putative clockcontrolled genes in skeletal muscle of the zebrafish. Am J Physiol Regul Integr
Comp Physiol, 2011.
Meyer zu Schwabedissen, H.E., R.G. Tirona, C.S. Yip, R.H. Ho, and R.B. Kim,
Interplay between the nuclear receptor pregnane X receptor and the uptake
transporter organic anion transporter polypeptide 1A2 selectively enhances
estrogen effects in breast cancer. Cancer Res, 2008. 68(22): p. 9338-47.
Li, X.B., S. Jiao, H. Sun, J. Xue, W.T. Zhao, L. Fan, G.H. Wu, and J. Fang, The
orphan nuclear receptor EAR2 is overexpressed in colorectal cancer and it
regulates survivability of colon cancer cells. Cancer Lett, 2011. 309(2): p. 137-44.
Lau, P., R.L. Fitzsimmons, S. Raichur, S.C. Wang, A. Lechtken, and G.E.
Muscat, The orphan nuclear receptor, RORalpha, regulates gene expression that
controls lipid metabolism: staggerer (SG/SG) mice are resistant to diet-induced
obesity. J Biol Chem, 2008. 283(26): p. 18411-21.
Raspe, E., H. Duez, P. Gervois, C. Fievet, J.C. Fruchart, S. Besnard, J. Mariani,
A. Tedgui, and B. Staels, Transcriptional regulation of apolipoprotein C-III gene
expression by the orphan nuclear receptor RORalpha. J Biol Chem, 2001. 276(4):
p. 2865-71.
Schrader, M., C. Danielsson, I. Wiesenberg, and C. Carlberg, Identification of
natural monomeric response elements of the nuclear receptor RZR/ROR. They
also bind COUP-TF homodimers. J Biol Chem, 1996. 271(33): p. 19732-6.
Mulholland, D.J., S. Dedhar, G.A. Coetzee, and C.C. Nelson, Interaction of
nuclear receptors with the Wnt/beta-catenin/Tcf signaling axis: Wnt you like to
know? Endocr Rev, 2005. 26(7): p. 898-915.
Lee, J.M., I.S. Kim, H. Kim, J.S. Lee, K. Kim, H.Y. Yim, J. Jeong, J.H. Kim, J.Y.
Kim, H. Lee, S.B. Seo, M.G. Rosenfeld, K.I. Kim, and S.H. Baek, RORalpha
attenuates Wnt/beta-catenin signaling by PKCalpha-dependent phosphorylation
in colon cancer. Mol Cell, 2010. 37(2): p. 183-95.

109

160.
161.
162.
163.
164.
165.
166.
167.
168.
169.

170.
171.
172.
173.
174.

175.

Yang, X., M. Downes, R.T. Yu, A.L. Bookout, W. He, M. Straume, D.J.
Mangelsdorf, and R.M. Evans, Nuclear receptor expression links the circadian
clock to metabolism. Cell, 2006. 126(4): p. 801-10.
Hossain, P., B. Kawar, and M. El Nahas, Obesity and diabetes in the developing
world--a growing challenge. N Engl J Med, 2007. 356(3): p. 213-5.
Perret, F., P. Bovet, C. Shamlaye, F. Paccaud, and L. Kappenberger, High
prevalence of peripheral atherosclerosis in a rapidly developing country.
Atherosclerosis, 2000. 153(1): p. 9-21.
Schade, A.E. and A.D. Levine, Lipid raft heterogeneity in human peripheral
blood T lymphoblasts: a mechanism for regulating the initiation of TCR signal
transduction. J Immunol, 2002. 168(5): p. 2233-9.
Rosenfeld, R.S. and L. Hellman, The relation of plasma and biliary cholesterol to
bile acid synthesis in man. J Clin Invest, 1959. 38(8): p. 1334-8.
Verschoor-Klootwyk, A.H., L. Verschoor, S. Azhar, and G.M. Reaven, Role of
exogenous cholesterol in regulation of adrenal steroidogenesis in the rat. J Biol
Chem, 1982. 257(13): p. 7666-71.
Rosenheim, O. and T.A. Webster, The Relation of Cholesterol to Vitamin D.
Biochem J, 1927. 21(1): p. 127-9.
Quintao, E., S.M. Grundy, and E.H. Ahrens, Jr., Effects of dietary cholesterol on
the regulation of total body cholesterol in man. J Lipid Res, 1971. 12(2): p. 23347.
Weber, C. and H. Noels, Atherosclerosis: current pathogenesis and therapeutic
options. Nat Med, 2011. 17(11): p. 1410-22.
Diraison, F., P. Moulin, and M. Beylot, Contribution of hepatic de novo
lipogenesis and reesterification of plasma non esterified fatty acids to plasma
triglyceride synthesis during non-alcoholic fatty liver disease. Diabetes Metab,
2003. 29(5): p. 478-85.
Rudel, L.L., J.M. Felts, and M.D. Morris, Exogenous cholesterol transport in
rabbit plasma lipoproteins. Biochem J, 1973. 134(2): p. 531-7.
Yuan, G., J. Wang, and R.A. Hegele, Heterozygous familial
hypercholesterolemia: an underrecognized cause of early cardiovascular disease.
CMAJ, 2006. 174(8): p. 1124-9.
Miller, N.E., A. La Ville, and D. Crook, Direct evidence that reverse cholesterol
transport is mediated by high-density lipoprotein in rabbit. Nature, 1985.
314(6006): p. 109-11.
Friedlander, Y., J.D. Kark, M. Fainaru, M. Gotsman, and Y. Stein, Aggregation of
plasma lipids and lipoproteins in families with and without coronary heart
disease. Atherosclerosis, 1985. 57(2-3): p. 235-47.
Pazzucconi, F., F. Dorigotti, G. Gianfranceschi, G. Campagnoli, M. Sirtori, G.
Franceschini, and C.R. Sirtori, Therapy with HMG CoA reductase inhibitors:
characteristics of the long-term permanence of hypocholesterolemic activity.
Atherosclerosis, 1995. 117(2): p. 189-98.
Grundy, S.M., E.H. Ahrens, Jr., and G. Salen, Interruption of the enterohepatic
circulation of bile acids in man: comparative effects of cholestyramine and ileal
exclusion on cholesterol metabolism. J Lab Clin Med, 1971. 78(1): p. 94-121.

110

176.
177.

178.
179.

180.

181.
182.

183.
184.
185.
186.

187.

188.

Weller, J.I., Maximum likelihood techniques for the mapping and analysis of
quantitative trait loci with the aid of genetic markers. Biometrics, 1986. 42(3): p.
627-40.
Morford, L.A., C. Davis, L. Jin, A. Dobierzewska, M.L. Peterson, and B.T. Spear,
The oncofetal gene glypican 3 is regulated in the postnatal liver by zinc fingers
and homeoboxes 2 and in the regenerating liver by alpha-fetoprotein regulator 2.
Hepatology, 2007. 46(5): p. 1541-7.
Pachnis, V., A. Belayew, and S.M. Tilghman, Locus unlinked to alpha-fetoprotein
under the control of the murine raf and Rif genes. Proc Natl Acad Sci U S A,
1984. 81(17): p. 5523-7.
Bernhardsson, C., I. Bjorkhem, H. Danielsson, and K. Wikvall, 12alphahydroxylation of 7alpha-hydroxy-4-cholesten-3-one by a reconstituted system
from rat liver microsomes. Biochem Biophys Res Commun, 1973. 54(3): p. 10308.
Wang, J., M. Olin, B. Rozell, I. Bjorkhem, C. Einarsson, G. Eggertsen, and M.
Gafvels, Differential hepatocellular zonation pattern of cholesterol 7alphahydroxylase (Cyp7a1) and sterol 12alpha-hydroxylase (Cyp8b1) in the mouse.
Histochem Cell Biol, 2007. 127(3): p. 253-61.
Goldberg, A.P., A. Chait, and J.D. Brunzell, Postprandial adipose tissue
lipoprotein lipase activity in primary hypertriglyceridemia. Metabolism, 1980.
29(3): p. 223-9.
Moen, C.J., A.P. Tholens, P.J. Voshol, W. de Haan, L.M. Havekes, P. Gargalovic,
A.J. Lusis, K.W. van Dyk, R.R. Frants, M.H. Hofker, and P.C. Rensen, The
Hyplip2 locus causes hypertriglyceridemia by decreased clearance of
triglycerides. J Lipid Res, 2007. 48(10): p. 2182-92.
Peinado-Onsurbe, J., B. Staels, S. Deeb, I. Ramirez, M. Llobera, and J. Auwerx,
Neonatal extinction of liver lipoprotein lipase expression. Biochim Biophys Acta,
1992. 1131(3): p. 281-6.
Wanless, I.R. and J.S. Lentz, Fatty liver hepatitis (steatohepatitis) and obesity: an
autopsy study with analysis of risk factors. Hepatology, 1990. 12(5): p. 1106-10.
Caldwell, S.H., D.H. Oelsner, J.C. Iezzoni, E.E. Hespenheide, E.H. Battle, and
C.J. Driscoll, Cryptogenic cirrhosis: clinical characterization and risk factors for
underlying disease. Hepatology, 1999. 29(3): p. 664-9.
Takamatsu, S., N. Noguchi, A. Kudoh, N. Nakamura, T. Kawamura, K.
Teramoto, T. Igari, and S. Arii, Influence of risk factors for metabolic syndrome
and non-alcoholic fatty liver disease on the progression and prognosis of
hepatocellular carcinoma. Hepatogastroenterology, 2008. 55(82-83): p. 609-14.
Visser, M.P., M.T. Krill, A.M. Muijtjens, G.M. Willems, and W.T. Hermens,
Distribution of enzymes in dog heart and liver; significance for assessment of
tissue damage from data on plasma enzyme activities. Clin Chem, 1981. 27(11):
p. 1845-50.
Beale, G., D. Chattopadhyay, J. Gray, S. Stewart, M. Hudson, C. Day, P.
Trerotoli, G. Giannelli, D. Manas, and H. Reeves, AFP, PIVKAII, GP3, SCCA-1
and follisatin as surveillance biomarkers for hepatocellular cancer in nonalcoholic and alcoholic fatty liver disease. BMC Cancer, 2008. 8: p. 200.

111

189.

190.
191.
192.

193.
194.

195.

196.
197.
198.
199.
200.
201.
202.

Kleiner, D.E., E.M. Brunt, M. Van Natta, C. Behling, M.J. Contos, O.W.
Cummings, L.D. Ferrell, Y.C. Liu, M.S. Torbenson, A. Unalp-Arida, M. Yeh,
A.J. McCullough, and A.J. Sanyal, Design and validation of a histological
scoring system for nonalcoholic fatty liver disease. Hepatology, 2005. 41(6): p.
1313-21.
Hui, J.M., A. Hodge, G.C. Farrell, J.G. Kench, A. Kriketos, and J. George,
Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology,
2004. 40(1): p. 46-54.
Liangpunsakul, S. and N. Chalasani, Treatment of Nonalcoholic Fatty Liver
Disease. Curr Treat Options Gastroenterol, 2003. 6(6): p. 455-463.
Pardina, E., J.A. Baena-Fustegueras, R. Llamas, R. Catalan, R. Galard, A.
Lecube, J.M. Fort, M. Llobera, H. Allende, V. Vargas, and J. Peinado-Onsurbe,
Lipoprotein lipase expression in livers of morbidly obese patients could be
responsible for liver steatosis. Obes Surg, 2009. 19(5): p. 608-16.
Jakobsson, A., R. Westerberg, and A. Jacobsson, Fatty acid elongases in
mammals: their regulation and roles in metabolism. Prog Lipid Res, 2006. 45(3):
p. 237-49.
Zadravec, D., A. Brolinson, R.M. Fisher, C. Carneheim, R.I. Csikasz, J. BertrandMichel, J. Boren, H. Guillou, M. Rudling, and A. Jacobsson, Ablation of the verylong-chain fatty acid elongase ELOVL3 in mice leads to constrained lipid storage
and resistance to diet-induced obesity. FASEB J, 2010. 24(11): p. 4366-77.
Haukeland, J.W., J.K. Damas, Z. Konopski, E.M. Loberg, T. Haaland, I. Goverud,
P.A. Torjesen, K. Birkeland, K. Bjoro, and P. Aukrust, Systemic inflammation in
nonalcoholic fatty liver disease is characterized by elevated levels of CCL2. J
Hepatol, 2006. 44(6): p. 1167-74.
Seki, S., T. Kitada, T. Yamada, H. Sakaguchi, K. Nakatani, and K. Wakasa, In
situ detection of lipid peroxidation and oxidative DNA damage in non-alcoholic
fatty liver diseases. J Hepatol, 2002. 37(1): p. 56-62.
Vacher, J., S.A. Camper, R. Krumlauf, R.S. Compton, and S.M. Tilghman, raf
regulates the postnatal repression of the mouse alpha-fetoprotein gene at the
posttranscriptional level. Mol Cell Biol, 1992. 12(2): p. 856-64.
Jin, L., L. Long, M.A. Green, and B.T. Spear, The alpha-fetoprotein enhancer
region activates the albumin and alpha-fetoprotein promoters during liver
development. Dev Biol, 2009. 336(2): p. 294-300.
Micsenyi, A., X. Tan, T. Sneddon, J.H. Luo, G.K. Michalopoulos, and S.P.
Monga, Beta-catenin is temporally regulated during normal liver development.
Gastroenterology, 2004. 126(4): p. 1134-46.
Ilyas, M., I.P. Tomlinson, A. Rowan, M. Pignatelli, and W.F. Bodmer, Betacatenin mutations in cell lines established from human colorectal cancers. Proc
Natl Acad Sci U S A, 1997. 94(19): p. 10330-4.
Torbenson, M., R. Kannangai, S. Abraham, F. Sahin, M. Choti, and J. Wang,
Concurrent evaluation of p53, beta-catenin, and alpha-fetoprotein expression in
human hepatocellular carcinoma. Am J Clin Pathol, 2004. 122(3): p. 377-82.
Nagae, G., T. Isagawa, N. Shiraki, T. Fujita, S. Yamamoto, S. Tsutsumi, A.
Nonaka, S. Yoshiba, K. Matsusaka, Y. Midorikawa, S. Ishikawa, H. Soejima, M.
Fukayama, H. Suemori, N. Nakatsuji, S. Kume, and H. Aburatani, Tissue-specific
112

203.

204.

205.
206.

207.
208.
209.
210.

211.

212.
213.
214.

demethylation in CpG-poor promoters during cellular differentiation. Hum Mol
Genet, 2011. 20(14): p. 2710-21.
You, J.S., T.K. Kelly, D.D. De Carvalho, P.C. Taberlay, G. Liang, and P.A.
Jones, OCT4 establishes and maintains nucleosome-depleted regions that provide
additional layers of epigenetic regulation of its target genes. Proc Natl Acad Sci
U S A, 2011. 108(35): p. 14497-502.
Tiniakos, D., D.A. Spandidos, A. Kakkanas, A. Pintzas, L. Pollice, and G.
Tiniakos, Expression of ras and myc oncogenes in human hepatocellular
carcinoma and non-neoplastic liver tissues. Anticancer Res, 1989. 9(3): p. 71521.
Hsu, I.C., R.A. Metcalf, T. Sun, J.A. Welsh, N.J. Wang, and C.C. Harris,
Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature,
1991. 350(6317): p. 427-8.
Mazure, N.M., C. Chauvet, B. Bois-Joyeux, M.A. Bernard, H. Nacer-Cherif, and
J.L. Danan, Repression of alpha-fetoprotein gene expression under hypoxic
conditions in human hepatoma cells: characterization of a negative hypoxia
response element that mediates opposite effects of hypoxia inducible factor-1 and
c-Myc. Cancer Res, 2002. 62(4): p. 1158-65.
Taube, J.H., K. Allton, S.A. Duncan, L. Shen, and M.C. Barton, Foxa1 functions
as a pioneer transcription factor at transposable elements to activate Afp during
differentiation of embryonic stem cells. J Biol Chem, 2010. 285(21): p. 16135-44.
Chauvet, C., B. Bois-Joyeux, E. Berra, J. Pouyssegur, and J.L. Danan, The gene
encoding human retinoic acid-receptor-related orphan receptor alpha is a target
for hypoxia-inducible factor 1. Biochem J, 2004. 384(Pt 1): p. 79-85.
Kim, E.J., Y.G. Yoo, W.K. Yang, Y.S. Lim, T.Y. Na, I.K. Lee, and M.O. Lee,
Transcriptional activation of HIF-1 by RORalpha and its role in hypoxia
signaling. Arterioscler Thromb Vasc Biol, 2008. 28(10): p. 1796-802.
McGrane, M.M., J.S. Yun, A.F. Moorman, W.H. Lamers, G.K. Hendrick, B.M.
Arafah, E.A. Park, T.E. Wagner, and R.W. Hanson, Metabolic effects of
developmental, tissue-, and cell-specific expression of a chimeric
phosphoenolpyruvate carboxykinase (GTP)/bovine growth hormone gene in
transgenic mice. J Biol Chem, 1990. 265(36): p. 22371-9.
Colletti, M., C. Cicchini, A. Conigliaro, L. Santangelo, T. Alonzi, E. Pasquini, M.
Tripodi, and L. Amicone, Convergence of Wnt signaling on the HNF4alphadriven transcription in controlling liver zonation. Gastroenterology, 2009. 137(2):
p. 660-72.
Seki, S., T. Kitada, and H. Sakaguchi, Clinicopathological significance of
oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res,
2005. 33(2): p. 132-4.
Hillebrandt, S., C. Goos, S. Matern, and F. Lammert, Genome-wide analysis of
hepatic fibrosis in inbred mice identifies the susceptibility locus Hfib1 on
chromosome 15. Gastroenterology, 2002. 123(6): p. 2041-51.
Kruth, H.S., Macrophage foam cells and atherosclerosis. Front Biosci, 2001. 6: p.
D429-55.

113

215.
216.

Frayn, K.N., C.M. Williams, and P. Arner, Are increased plasma non-esterified
fatty acid concentrations a risk marker for coronary heart disease and other
chronic diseases? Clin Sci (Lond), 1996. 90(4): p. 243-53.
Nagel, S., B. Schneider, A. Rosenwald, C. Meyer, M. Kaufmann, H.G. Drexler,
and R.A. Macleod, t(4;8)(q27;q24) in Hodgkin lymphoma cells targets
phosphodiesterase PDE5A and homeobox gene ZHX2. Genes Chromosomes
Cancer, 2011. 50(12): p. 996-1009.

114

Curriculum Vitae
Erica L Clinkenbeard
2380 Lake Park Rd #914
Lexington, KY 40502
(859) 409-3569
e.l.flei3@uky.edu
EDUCATION
2002-2006

Ohio University
BS, Forensic Chemistry

PUBLICATIONS
Kojima F, Kapoor M, Yang L, Fleishaker EL, Ward MR, Monrad SU, Kottangada PC,
Pace CQ, Clark JA, Woodward JG, Crofford LJ. Defective generation of a humoral
immune response is associated with a reduced incidence and severity of collagen-induced
arthritis in microsomal Prostaglandin E Synthase-1 null mice. J Immunol. 2008 June 15:
180(12):8361-8
Opel, KL, Fleishaker, EL, Nicklas, JA, Buel, E., McCord,BR. Evaluation and
quantification of nuclear DNA from human telogen hairs. J Forensic Sci. 2008 Jul;
53(4):853-7. Erratum in: J Forensic Sci. 2008 Nov; 53(6):1501
POSTERS
April ,2011, Experimental Biology Meeting, Washington,D.C. Erica Fleishaker, James
Butler, Martha Peterson, Brett Spear. Beta-catenin and nuclear receptors regulate zonal
AFP enhancer expression. Poster Presentation
March 22,2011, Markey Cancer Center Research Day, Lexington, KY. Erica Fleishaker,
James Butler, Martha Peterson, Brett Spear. Beta-catenin and nuclear receptors regulate
zonal AFP enhancer expression. Poster Presentation
October, 2010, Microbiology, Immunology,Molecular Genetics Department Retreat,
Lexington, KY. Erica Fleishaker, James Butler, Martha Peterson, Brett Spear. Betacatenin and nuclear receptors regulate zonal AFP enhancer expression. Poster
Presentation

115

Arpril 27, 2010, Experimental Biology Meeting, Anaheim, CA. Poster presentation
entitled “Zhx2 protects the liver from high fat diet-induced liver damage”. Erica
L.Fleishaker, Martha Peterson, Brett T. Spear
April 14, 2010, Markey Cancer Center Research Day, Lexington, KY. Poster
presentation entitled “Zhx2 protects the liver from high fat diet-induced liver damage”.
Erica L. Fleishaker, Martha Peterson, Brett T. Spear.
PRESENTATIONS
February 4, 2011 – “AFP enhancer 3: Insights into liver zonality” Department of
Microbiology, Immunology and Molecular Genetics, University of Kentucky
March 5, 2010 – “New insights into Zhx2 and liver function” Department of
Microbiology, Immunology and Molecular Genetics, University of Kentucky
April 24, 2009 – “Zhx2: A Novel Regulator of Hepatic Lipid Metabolism” Department of
Microbiology, Immunology and Molecular Genetics, University of Kentucky
September 21, 2007 – “Alternative Methods to Ameliorate Pathology of Duchenne’s
Muscular Dystrophy” Department of Microbiology, Immunology and Molecular
Genetics, University of Kentucky
AWARDS
March 22, 2011, Markey Cancer Center Research Day, Lexington, KY. 1st place basic
science graduate student poster.

116

